Carboxylated polyamine derivatives as transfection reagents
By introducing polyamine derivatives with specific carboxylated and hydrophobic substituents to the polyamine, the efficiency and stability of existing transfection agents in a variety of cell types are solved, and efficient nucleic acid and polyanion transfection is achieved. Reduces toxicity and is better than the performance of commercially available transfectants.
Patent Information
- Application Number
- CN202011254751.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2012-10-08
- Filing Date
- 2013-10-02
- Publication Date
- 2024-11-01
- Estimated Expiration
- 2033-10-02
AI Technical Summary
The efficiency and signal-to-noise ratio of existing transfectants when passing through various cell types are insufficient, and there are toxicity and stability problems, making it difficult to achieve efficient nucleic acid and polyanion transfection.
A polyamine derivative was developed to form a complex with a specific logP value by introducing carboxylated substituents and hydrophobic substituents on the polyamine to improve the stability and cell penetration of the transfection agent, including multiple A combination of amine moieties, carboxylated substituents and hydrophobic substituents are used to form complexes with nucleic acids or proteins for transfection.
Highly efficient transfection of various cell types is achieved, signal-to-noise ratio is improved, and toxicity is reduced, and the performance is better than that of commercially available transfection agents.
Smart Images

Figure BDA0002772745460000101 
Figure BDA0002772745460000111 
Figure BDA0002772745460000112
Abstract
Description
[0001] The present application is a divisional application of an application filed on October 2, 2013, with application number 201380052457.0 and invention name “Carboxylated polyamine derivatives as transfection reagents”. Field of the Invention
[0002] The present invention relates to polyamine derivatives and the use of polyamine derivatives for transfecting nucleic acids and other polyanions into cells. The present invention also relates to a method for transfecting polyanions into cells, and to kits and polyamine derivatives for use therein. The polyamine derivatives of the present invention are effective transfectants with very low toxicity and can be used to transfect a variety of different cell types. Background Art
[0003] Transfection is the introduction of exogenous material into a cell. In the context of transfection, "into a cell" means transporting the exogenous material across at least one biological membrane. It may further be transported to a cell compartment or organelle. In contrast, simply containing the material in an endosome, endocytic or phagocytic vesicle, or lysosome is not considered transfection.
[0004] Exogenous material may comprise molecules such as peptides, proteins, and nucleic acids of various types; the latter may be as small as oligonucleotides or as long as plasmids. Exogenous material may also comprise assemblies of such molecules. In any case, the above molecules or assemblies are large and hydrophilic, two features that hinder their cellular uptake alone. Transfection therefore requires the use of specific auxiliary agents. Among others, polyamines may be such agents. Polyamines form polycations in solution, promoting the formation of complexes with polyanions such as nucleic acids. These complexes are the actual transfection competent entities.
[0005] Boussif et al. (Proc Natl Acad Sci USA (1995), 92 (16): 7297-7301) or in US6013240) using branched polyethyleneimine (PEI) as a polyamine, demonstrating transfection of a complex of polyamine and plasmid. While continuing this concept, others have tried to improve the technology by various means. Strategies for improving transfection agents include:
[0006] (i) selecting a polycation of a specific size or configuration, such as PEI with a linear chain of a specific length (WO2009 / 016507);
[0007] (ii) using metabolically labile polymers of such polycations (Gosselin et al. (2001) Bioconj Chem, 12 (6): 989-994; Lynn et al. (2001) J Am Chem Soc 123 (33): 8155-8156; et al. WO2007 / 020060; Tanaka et al. WO2007 / 120479);
[0008] (iii) using a lipid mixture (Monahan et al. US 7,601,367); or
[0009] (iv) Chemical modification of the polymer backbone, such as grafting of aromatic amino acids (in WO2009 / 074970 to Adib et al.), grafting of histidine or imidazole groups (in WO2009 / 011402), alkylation as in Wakefield et al. (2005) Bioconj Chem 16(5):1204-1208 or modification with cholesterol (in US2007 / 0154447 to Ferguson et al.).
[0010] Hydrophobic modification improves membrane penetration of transfectants (see Wakefield et al.), but is associated with low stability of the complex in solution; the formulated material tends to form aggregates. Grafting of polyethylene glycol (PEG) (by Matar et al. in WO2009 / 021017 or in Rozema et al. (2007) Proc Natl Acad Sci USA 104(32):12982-12987) counteracts aggregation, but on the other hand it antagonizes biological activity and must be reversible, as shown in the Rozema publication.
[0011] It is evident from the many different strategies and from the large number of reports that the development of new transfection agents is the subject of intensive research. Their application is of great commercial importance; transfection reagents had a market capacity of approximately 200 Mio USD in 2011 (Frost & Sullivan, Global Transfection Markets, N6F0-01).
[0012] The two most important criteria in the development and improvement of transfection agents are (i) a high signal-to-noise ratio and (ii) efficient transfection across a large number of different cell types. The signal-to-noise ratio describes the effectiveness of the transfection complex compared to the transfection agent alone or to transfection complexes containing unrelated nucleic acids.
[0013] It is therefore an object of the present invention to provide a transfection agent for transfecting polyanions into cells and a method for transfecting cells. Another object is to provide a transfection agent that is superior to commercially available materials in terms of criteria (a) and / or (b). In view of the large number and variety of methods previously used, no specific principles have been found that teach this invention. SUMMARY OF THE INVENTION
[0014] The above objectives are achieved through the following means:
[0015] (1) Use of a polyamine derivative for transfecting polyanions into cells, the polyamine comprising:
[0016] a polyamine moiety comprising a plurality of amino groups;
[0017] a plurality of carboxylated substituents comprising carboxyl groups bonded to the amino groups of the polyamine moiety via a hydrophobic linker; and
[0018] a plurality of hydrophobic substituents bonded to the amino groups of the polyamine moiety;
[0019] The hydrophobic linker has a logP of 3 to 20, the logP being measured for a compound obtained from the linker by replacing bonds binding the linker to the carboxyl group and the amino group of the polyamine with bonds binding to a hydrogen atom; and
[0020] The hydrophobic substituent has a logP of 1.5 to 20, which is measured for a compound obtained by replacing a bond of the hydrophobic substituent to the amino group of the polyamine moiety with a bond to a hydrogen atom from the hydrophobic substituent.
[0021] (2) Use of a polyamine derivative for transfecting polyanions into cells, the polyamine comprising:
[0022] a polyamine moiety comprising a plurality of amino groups;
[0023] a plurality of carboxylated substituents comprising a carboxyl group bound to an amino group of the polyamine moiety via a hydrophobic linker, wherein each of the carboxylated substituents comprises 6 to 40 carbon atoms, preferably 6 to 20 carbon atoms, more preferably 8 to 18 carbon atoms, and each of the hydrophobic linkers may comprise 1 to 3 heteroatoms selected from O, N and S; and
[0024] A plurality of hydrophobic substituents, the hydrophobic substituents being bonded to the amino groups of the polyamine moieties, wherein each of the hydrophobic substituents comprises at least 2 carbon atoms, preferably 6 to 40 carbon atoms, and may comprise 1 to 3 heteroatoms selected from O, N and S when the hydrophobic substituents have at least 6 carbon atoms.
[0025] (3) The use according to item 1 or 2, wherein each of the carboxylated substituents of the polyamine derivative comprises any one or more of the following groups as the hydrophobic linker: an alkylene group, an alkenylene group, an alkynylene group, a cycloalkylene group, a cycloalkenylene group, an arylene group, and combinations thereof; and / or
[0026] Each of the hydrophobic substituents of the polyamine derivatives comprises any one or more of the following groups: alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, and combinations thereof.
[0027] (4) The polyamine derivative as defined in item 1 or 2.
[0028] (5) Polyalkylenimine derivatives having one or more carboxyalkyl substituents and one or more hydrophobic substituents, wherein the carboxyalkyl substituents contain 6 to 40 carbon atoms, and the hydrophobic substituents are selected from hydrocarbon substituents having at least 2 carbon atoms, preferably 6 to 40 carbon atoms, wherein each of the hydrophobic substituents may be an alkyl group or may contain an alkyl group and / or each of the hydrophobic substituents may be an aryl group or may contain an aryl group.
[0029] (6) The polyalkyleneimine derivative according to item 5, wherein the carboxyalkyl substituent and the hydrophobic substituent in the polyalkyleneimine derivative have a molar ratio (C / A ratio) of 10:1 to 0.1:1, preferably the C / A ratio of these groups is 3:1 to 0.33:1.
[0030] (7) The polyamine derivative or polyalkyleneimine derivative according to any one of items 4 to 6, wherein the carboxylated substituents are all the same and the hydrophobic substituents are all the same, and the total number of carbon atoms in one carboxylated substituent plus one hydrophobic substituent is 10 to 30, preferably 15 to 25.
[0031] (8) A complex of a nucleic acid or a protein with the polyamine derivative of the present invention.
[0032] (9) A kit comprising:
[0033] (i) a polyamine derivative as defined herein,
[0034] (ii) a buffer solution having a pH between 4 and 8, and
[0035] (iii) Optionally, an instruction manual.
[0036] (10) A method for transfecting cells with a nucleic acid or a protein, comprising mixing the nucleic acid or protein with a polyamine derivative as defined herein, for example in an aqueous buffer, and treating the cells with the mixture obtained in the previous step.
[0037] (11) A container comprising a plurality of compartments, wherein the compartments contain a lyophilized composition comprising a transfection agent, wherein the transfection agent may be a polyamine derivative as defined in any one of items 1 to 7 or may contain a polyamine derivative as defined in any one of items 1 to 7.
[0038] The present invention also provides:
[0039] (12) Use of carboxyalkyl-alkyl-polyamines for transfecting polyanions into cells.
[0040] (13) The use according to item 12, wherein the polyamine part of the carboxyalkyl-alkyl-polyamine is selected from the group consisting of polyalkyleneimines, polyallylamine, polyethyleneamine, polylysine and polyornithine, wherein the polyalkyleneimines are preferably polyethyleneimines, polypropylenimines, polybutylenimines or oligospermines or homologues thereof, and wherein the polyamine part contains 12 to 100,000 nitrogen atoms, more preferably 20 to 5,000 nitrogen atoms.
[0041] (14) The use according to any one of item 12 or 13, wherein the carboxyalkyl moiety is an aliphatic carboxyalkyl moiety having 4 to 40 carbon atoms, preferably 6 to 20 carbon atoms, more preferably 8 to 16 carbon atoms.
[0042] (15) The use according to any one of items 12 to 14, wherein the alkyl moiety is an aliphatic alkyl moiety having at least 2 carbon atoms, preferably 6 to 40 carbon atoms.
[0043] (16) The use according to any one of items 12 to 15, wherein all the carboxyalkyl parts of the carboxyalkyl-alkyl-polyamine are the same and all the alkyl parts are the same, and the total number of carbon atoms in the carboxyalkyl parts and the alkyl parts is 10 to 30, preferably 15 to 25.
[0044] (17) The use according to any one of items 12 to 16, wherein the carboxyalkyl-alkyl-polyamine is a linear carboxyalkyl-alkyl-polyalkyleneimine comprising a structural unit represented by the following formula (6):
[0045] -[CH2-NR 6 -(CH2) x ]- (6)
[0046] in
[0047] x is an integer from 1 to 10, wherein in different (CH2)x The value of x can be the same or different between groups.
[0048] R 6 For hydrogen, C r H 2r+1 or C s-1 H 2s-2 COOH
[0049] r is an integer from 2 to 40,
[0050] s is an integer from 4 to 40;
[0051] or
[0052] The carboxyalkyl-alkyl-polyamine is a branched carboxyalkyl-alkyl-polyalkylene imine comprising a structural unit represented by each of formula (7), formula (8) and formula (9):
[0053] -[CH2-NR 6 -(CH2) x ]- (7)
[0054] -[CH2-NR 7 -(CH2) x ]- (8)
[0055] -(CH2) y -NR 6 2 (9)
[0056] in
[0057] R 6 , x, r and s are as defined above, and
[0058] R 7 comprising one or more units selected from formula (7), formula (8) and formula (9);
[0059] y is an integer from 1 to 10, preferably an integer from 2 to 10, wherein multiple occurrences of (CH2) y The value of y can be the same or different between groups;
[0060] And wherein the number of nitrogen atoms per molecule of the linear carboxyalkyl-alkyl-polyalkyleneimine or the branched carboxyalkyl-alkyl-polyalkyleneimine is 12 to 100,000.
[0061] (18) The use according to any one of items 12 to 17, wherein the molar ratio of the carboxyalkyl part to the alkyl part in the carboxyalkyl-alkyl-polyamine is in the range of 6:1 to 0.33:1, preferably in the range of 2:1 to 0.5:1.
[0062] (19) The use according to any one of items 12 to 18, wherein at least 10 mol %, preferably 25 to 80 mol %, more preferably 30 to 60 mol % of the amino groups of the polyamine are substituted (substitution degree) by the carboxyalkyl group and the alkyl group.
[0063] (20) The use according to any one of items 12 to 19, wherein the polyanion is a nucleic acid.
[0064] (21) The polyalkyleneimine derivative according to item 5, which is a carboxyalkyl-alkyl-polyamine, wherein the carboxyalkyl-alkyl-polyamine has one type of carboxyalkyl part and one type of alkyl part, and the total number of carbon atoms in the carboxyalkyl part of this type and the alkyl part of this type is 10 to 30, preferably 15 to 25.
[0065] (22) The polyalkyleneimine derivative according to item 21, wherein the polyalkyleneimine derivative is a branched polyethyleneimine, wherein further the carboxyalkyl portion has 8 to 16 carbon atoms and wherein the alkyl portion has 8 to 10, preferably about 9 carbon atoms.
[0066] (23) A complex of a nucleic acid and a carboxyalkyl-alkyl-polyamine as defined in any one of items 12 to 22 above.
[0067] (24) A kit comprising:
[0068] (i) a carboxyalkyl-alkyl-polyamine as defined in any one of items 12 to 19 or items 21 to 22,
[0069] (ii) a buffer solution having a pH value between 4 and 8 and an ionic strength of 0.2 mol / L or less, preferably 0.1 mol / L or less, and
[0070] (iii) Optionally, an instruction manual.
[0071] (25) The kit according to item 24, wherein the polyamine is provided in the form of a solution, and wherein the solvent is a lower alcohol selected from the group consisting of ethanol, propanol, 1,2-dihydroxypropane or isopropanol, or a mixture comprising water and 33 to 100% of such a lower alcohol.
[0072] (26) The kit according to item 24, wherein the polyamine is provided in a dry form.
[0073] (27) The kit according to item 24 or 26, wherein the polyamine is provided in a lyophilized form.
[0074] (28) The kit according to any one of items 24 to 27, wherein the polyamine is placed in a multi-well plate.
[0075] (29) The kit according to item 28, wherein the wells of the multi-well plate contain different amounts of the polyamine, preferably contain a gradient of the polyamine in adjacent wells or some of the wells are empty.
[0076] (30) A method for transfecting cells using polyanions, comprising: mixing the polyanion with a carboxyalkyl-alkyl-polyamine as defined in any one of items 12 to 22 in water or an aqueous buffer, and treating the cells with the mixture obtained in the previous step.
[0077] The polyamines are chemically modified using carboxylated substituents comprising carboxyl groups bonded to the polyamines via a hydrophobic linker and using hydrophobic substituents. The modified polyamines used in the present invention are represented as carboxylated, hydrophobized polyamines or modified polyamines or polyamine derivatives throughout the specification. In one embodiment, polyamines are chemically modified using carboxyalkyl substituents and alkyl substituents. These modified polyamines are represented as carboxyalkyl-alkyl-polyamines in this article. Surprisingly, it was found that the combination of the two modifications is superior to any single modification because a high signal-to-noise ratio and more effective transfection are achieved. The novel reagent has these results for many cell types and is also superior to those materials recorded in commercially available materials and the prior art. DETAILED DESCRIPTION OF THE INVENTION
[0078] The polyamine derivatives of the present invention have carboxylated substituents and hydrophobic substituents on the polyamines, wherein these substituents may each independently include one, two or three heteroatoms selected from oxygen, nitrogen or sulfur. The carboxyalkyl-alkyl-polyamines of the present invention are polyamine derivatives having carboxyalkyl substituents as the carboxylated substituents and alkyl substituents as the hydrophobic substituents on the polyamines.
[0079] Polyamine derivatives of the present invention can be obtained by methods known in the art. A possible method is the derivatization of polyamines with halogenated carboxylic acids and halogenated hydrophobic compounds, wherein the halogenated carboxylic acids form the carboxylated substituents when the halogen is substituted by the amino nucleophilicity of polyamines, and the halogenated hydrophobic compounds form the hydrophobic substituents when the halogen is substituted by the amino nucleophilicity of polyamines. Carboxylalkyl-alkyl-polyamines of the present invention can be obtained similarly. A possible method is the alkylation of polyamines with halogenated alkanoic acids and with halogenated alkanes by nucleophilic substitution. Halogen or halogenated substituents can be chlorine, bromine or iodine atoms, and preferably, they are bromine. More details about the preparation of polyamine derivatives and carboxylalkyl-alkyl-polyamines are provided below.
[0080] Polyamine
[0081] The polyamines that can be used as the starting materials for producing the polyamine derivatives of the present invention are polymers with multiple nitrogen atoms that form multiple amino groups. These nitrogen atoms can be charged in aqueous solution through protonation. Most aliphatic amines have a pK greater than 8 or 9, which means that they are substantially or completely charged in aqueous solutions with a pH value of about 7.4 (physiological pH) or lower pH values.
[0082] Amine moieties such as pyridine or aniline having a pK below 6 are less preferred amino groups of the polyamine. The pK values of various amines are readily available as they are often mentioned in the respective articles of English Wikipedia (en.wikipedia.org) or they can be calculated using software such as the ACD / pKa database (Advanced Chemistry Development, Ontario, Canada).
[0083] The multiple nitrogen atoms of the polyamines may be primary, secondary, tertiary and / or quaternary amino groups, which may also be part of a ring system. Primary, secondary, tertiary and / or quaternary amino groups may be present in the same polyamine molecule. Primary, secondary and tertiary amino groups are preferred because they can be alkylated as described above. The polyamines may further include terminal groups (end groups), which may also be amino groups; however, such terminal groups may also be initiators or terminators for the polymerization reaction used to make the polyamines.
[0084] For some linear polyamines, the internal amino group may be a secondary amino group; examples of such polyamines are polyalkyleneimines. In other linear polyamines, the amino group is not part of the polymer backbone, but is part of a side chain or the amino group itself forms a side chain. For branched polyamines, the internal amino group that forms a branch point is generally a tertiary amino group, while the internal amino group that does not form a branch point is generally a secondary amino group. The branches of such polymers are generally terminated by primary amino groups.
[0085] In the following, polyamines useful for making the polyamine derivatives of the present invention, in particular the carboxyalkyl-alkyl-polyamines, are described. Thereafter, the polyamine derivatives and the carboxyalkyl-alkyl-polyamines of the present invention are described.
[0086] In a first general embodiment, the multiple nitrogen atoms of the polyamines useful for preparing the polyamine derivatives and carboxyalkyl-alkyl-polyamines of the present invention are part of the polymer backbone of the polyamine. The polyamine may be a linear polyamine having multiple nitrogen atoms in the polymer chain. Such a polyamine may be a polyalkylene imine comprising multiple units of formula (1):
[0087] (1)-[CH2-NR 1 -(CH2) x ]-,
[0088] Where x is an integer from 1 to 10 and R 1 In one embodiment, x may be an integer from 1 to 5, preferably 1, 2 or 3. In different (CH2) x The value of x may be the same or different between the groups. For example, along the polymer chain of the polyamine, x may vary between two or three different values of x, such as between 2 and 3, between 2 and 4, or between 2 and 5. In the polyamine represented by formula (1), substantially all of the amino groups in the polymer chain are secondary amino groups.
[0089] If m is the number of repeating units represented by formula (1) in the polyalkylene imine, m may be an integer of 12 to 100,000, preferably 12 to 20,000, more preferably 20 to 10,000, most preferably 20 to 5,000.
[0090] Examples of polyamines which become the polyamine part of the polyamine derivative by alkylation, in particular by nucleophilic substitution, are polyalkyleneimines, preferably polyethyleneimine, polypropyleneimine, polybutyleneimine or oligospermine or their homologues. The polyamine part may contain 12 to 20000 nitrogen atoms per polyamine molecule, more preferably 20 to 10000 nitrogen atoms, or as defined above for m.
[0091] Alternatively, the polyamine that can become the polyamine part of the polyamine derivative by alkylation, especially by nucleophilic substitution, can be a branched polyamine, preferably a branched polyalkylene imine. Such branched polyalkylene imine can be defined by a structural unit having each of the following formulae (2) to (4):
[0092] -[CH2-NR 1 -(CH2) x ]- (2)
[0093] -[CH2-NR 2 -(CH2) x ]- (3)
[0094] -(CH2) y -NR 3 twenty four)
[0095] in
[0096] R 1 and x are as defined above;
[0097] R 2 Comprising units of formula (2), formula (3) and / or formula (4);
[0098] R 3 represents hydrogen; and
[0099] Y is an integer from 1 to 10, wherein in different (CH2) y The value of y may be the same or different between groups.
[0100] In the branched polyalkylene imine, the main chain thereof may be formed of a divalent unit represented by formula (2) containing a secondary amino group. In addition, the branched polyalkylene imine, in particular, has a main chain containing at least one unit represented by formula (3), wherein the unit represented by formula (3) contains a branch point and R 2 The branched polymer chain contains at least one, usually a plurality of, units of formula (2), and may further contain one or more units of formula (3), resulting in further branching. Thus, the branched polyalkylene imine may be a dendrimer or a branched polymer. In many cases, these branched polyalkylene imines contain structural components (2), (3) and (4) in a random order, resulting in an irregular structure or a random polyamine. The monovalent group of formula (4) defines the end groups of the polyalkylene imine that may be present on the main chain as well as on the branches. The x, R in each of the various structures of formula (2), formula (3) and formula (4) present in the polyalkylene imine 2 and R 3 Can be the same or different.
[0101] The degree of branching in the branched polyalkyleneimines may be from 1 to 40%, preferably from 10 to 40%, more preferably from 15 to 30%. A person skilled in the art knows how to quantify the branching of a polymer, for example by pH titration and quantifying the titration curve in different compartments, or by 1H-NMR measurements.
[0102] A measure of the degree of branching in a branched polyalkyleneimine is the ratio of primary, secondary and tertiary amino groups. While a linear polyalkyleneimine has only secondary amino groups as internal amino groups, a branched polyalkyleneimine has tertiary amino groups such as those shown in formula (3), the amount of which increases with increasing branching. The molar ratio of primary amino groups in the branched polyamine may be 1 to 40%, preferably 15 to 30%. The molar ratio of secondary amino groups may be 15 to 85%, preferably 30 to 70%. The molar ratio of tertiary amino groups may be 1 to 40%, preferably 15 to 30%.
[0103] Examples of branched polyamines that can become the polyamine portion of the polyamine derivative or the polyamine portion of the carboxyalkyl-alkyl-polyamine are branched polyalkyleneimines, preferably branched polyethyleneimines, branched polypropyleneimines, or branched polybutyleneimines. Branched polyamines such as branched polyalkyleneimines can have 12 to 100,000 nitrogen atoms per polyamine molecule, more preferably 20 to 20,000 nitrogen atoms. In other embodiments, the number of nitrogen atoms in such polymers is 20 to 5000 nitrogen atoms per polyamine molecule.
[0104] Examples of polyamines having a charged backbone in aqueous medium at neutral pH that are useful in producing the polyamine derivatives or carboxyalkyl-alkyl-polyamines of the present invention are listed in Table 1 below:
[0105] Table 1:
[0106]
[0107]
[0108] In Table 1, Mr represents a relative molecular weight expressed as a number average molecular weight (Mn).
[0109] Another example of a branched polyamine is polyethyleneimine having the following structure with CAS number 9002-98-6:
[0110]
[0111] n is an integer such that the number average molecular weight Mn is about 10 000. It is commercially available from Sigma-Aldrich under catalog number 408727. Other branched polyamines are listed in the examples.
[0112] Polyamines can also form multimeric assemblies of polyamine oligomers. Examples of multimeric assemblies are described in Gosselin et al. (2001) Bioconj Chem, 12 (6): 989-994; Lynn et al. (2001) J Am Chem Soc 123 (33): 8155-8156; et al., or WO2007 / 020060, or Tanaka et al., WO2007 / 120479.
[0113] In a second general embodiment, the charged nitrogen atoms of the polyamines useful for preparing the polyamine derivatives or carboxyalkyl-alkyl-polyamines of the present invention are not part of the polymer backbone, but are present in the side chains of the polyamines. In some embodiments, the polyamines may be derivatives of polyethylene, such as polyallylamine, polyethyleneamine, cationized polyacrylates, or polyethylene ethers shown in structure (5),
[0114] (5)-[CH2-CHR 4 ] p -,
[0115] in
[0116] R 4Selected from -NH2, -CH2-NH2, -O-CH2-CH2-NH2 or -C(=O)OR 5 ,in
[0117] R 5 Selected from –CH2-CH2-NH2, –CH2-CH2-NH-CH3, –CH2-CH2-N-(CH3)2 and –CH2-CH2-N-(CH2-CH3)2.
[0118] The variable p is an integer representing the size of the polymer and may vary from 20 to about 50000. In a preferred embodiment, p is between 20 and 5000, and in a more preferred embodiment, p is between 100 and 2000.
[0119] In other embodiments, the polyamine is a polypeptide such as polylysine, polyornithine, polyarginine, etc. The number of amino acid residues in these polypeptides may be as defined above for p. In still other embodiments, the polyamine may have a sugar backbone, such as chitosan.
[0120] As with the first general embodiment, the polymers of the second general embodiment may also be linear, branched, or dendrimer-type. They may also be polymeric assemblies of polyamine oligomers.
[0121] Examples of polyamines having charged side chains for use in the second general embodiment are listed in Table 2 below:
[0122] Table 2
[0123]
[0124] To achieve high performance in transfection, polyamines such as those described above are modified with carboxylated substituents and hydrophobic substituents, such as with carboxyalkyl and alkyl substituents, to obtain the polyamine derivatives of the present invention. The carboxylated substituent may contain at least 6 carbon atoms.
[0125] Carboxylation Substituent
[0126] The carboxylated substituent comprises a carboxyl group bonded to an amino group of a polyamine via a hydrophobic linker, the hydrophobic linker may have a distribution coefficient logP of 3 to 20, preferably 3 to 10 and more preferably 4 to 9, the logP being determined for a compound obtained by replacing the bonds binding the linker to the carboxyl group and the amino group of the polyamine with bonds binding to a hydrogen atom from the linker. Methods for determining logP are known to those skilled in the art and include experimentally determining the distribution of compounds between water and 1-octanol, or obtaining these values from reference sources such as Wikipedia (English version), or calculating logP using software such as ACD / Labs7.0 (Advanced Chemistry Development, Ontario, Canada).
[0127] The carboxylated substituent may include one or two carboxyl groups, preferably one carboxyl group. Each carboxylated substituent may include 6 to 40 carbon atoms, preferably 6 to 20 carbon atoms, and more preferably 8 to 16 carbon atoms. The hydrophobic linker of the carboxylated substituent may include 1 to 3, preferably 1 or 2 heteroatoms selected from O, N and S. Preferably, the heteroatoms are selected from O and S. In one embodiment, 1 or 2 heteroatoms selected from O, N and S, preferably selected from O and S, may be included in the hydrophobic linker. Therefore, the carboxylated substituent may be a carboxyalkyl group, or they may be a carboxyheteroalkyl group comprising 1 to 3 heteroatoms, and the heteroatoms are selected from O, N and S, preferably selected from O and S. Among the multiple carboxylated substituents of the polyamine derivative molecule, there may be only a carboxyalkyl group, only a carboxyheteroalkyl group, or there may be a carboxyalkyl group and a carboxyheteroalkyl group. In one embodiment, multiple carboxylated substituents are all carboxyalkyl groups. In another embodiment, the plurality of carboxylated substituents are all carboxyheteroalkyl groups.
[0128] When the carboxylated substituent is a carboxyalkyl group, the hydrocarbon portion of the carboxyalkyl group may be a saturated aliphatic hydrocarbon portion, an unsaturated aliphatic hydrocarbon portion, an alicyclic hydrocarbon portion, an aromatic hydrocarbon portion, or a group containing two or more of the above listed groups.
[0129] The example of carboxyl alkyl group is carboxylalkyl group, carboxyalkenyl group, carboxyalkynyl group, carboxycycloalkyl group, carboxycycloalkenyl group, carboxylalkylcycloalkyl group, carboxylcycloalkylalkyl group, carboxylalkylcycloalkylalkyl group, carboxyaryl group, carboxylalkylaryl group, carboxyarylalkyl group and carboxylalkylarylalkyl group. Hereinafter, the example and definition of the alkyl group combined with carboxyl group have also been provided in the part of hydrophobic substituent. A plurality of different such alkyl groups can be combined. However, the logP value and / or carbon number limit that provide above are applicable.
[0130] 1, 2 or 3, preferably 1 or 2 carbon atoms of the alkyl portion of the carboxylated substituent may be replaced with oxygen, nitrogen or sulfur to form a carboxyheteroalkyl group. It will be appreciated that any such substitution by a heteroatom will include adjustment of the attached hydrogen atoms to adjust to the valence of the heteroatom being exchanged. In a preferred embodiment, such carboxyheteroalkyl portion of the hydrophobic linker comprises one or more functional groups selected from -O-, -S-, -N(H)C(O)-, -C(O)O-, -OC(O)N(H)-, -C(O)-, -C(O)-N(H)-, -N(H)-C(O)-O-, -OC(O)- or -SS-.
[0131] In one aspect of the invention, the hydrophobic linker is an alkylene group or comprises an alkylene group, such as a straight or branched alkylene group, or a linker is a cycloalkylene group or comprises a cycloalkylene group. The alkylene group can be a normal alkylene group or an isoalkylene group. The example of the alkylene group is propylene, butylene, pentylene, hexylene, heptylene, octylene, nonylene, decylene, sub-undecylene, sub-dodecylene, sub-tetradecylene or sub-hexadecylene. The example of the cycloalkylene group is cyclopentylene, cyclohexylene and cycloheptylene. The example of the alkylcycloalkyl is methyl cyclopentylene, ethyl cyclopentylene, propyl cyclopentylene, butyl cyclopentylene, pentyl cyclopentylene, hexyl cyclopentylene, methyl cyclohexylene, ethyl cyclohexylene, propyl cyclohexylene, butyl cyclohexylene, pentyl cyclohexylene and hexyl cyclohexylene. One or more of these can be combined in the hydrophobic linker.
[0132] The carboxylated substituent can be carboxyalkyl or carboxycycloalkyl or can comprise carboxyalkyl or carboxycycloalkyl, and comprise 6 to 20. Such carboxylated substituent can be selected from the group consisting of carboxyl-normal alkyl group, the carboxyalkyl group of side chain or cyclocarboxyalkyl group and their structure or conformational isomer. In a preferred embodiment, carboxyalkyl is the acid radical group selected from the acid of hexanoic acid, heptanoic acid, octanoic acid, nonanoic acid, caprylic acid, undecanoic acid, dodecanoic acid, tetradecanoic acid, hexadecanoic acid, 2-cyclohexyl acetic acid, 4-cyclohexylbutyric acid, 6-cyclohexyl caproic acid, 2-(2', 3' or 4' ethylcyclohexyl)-acetic acid or 4-(2', 3' or 4' ethylcyclohexyl)-butyric acid or 6-(2', 3' or 4' ethylcyclohexyl)-hexanoic acid.
[0133] In another aspect of the present invention, the hydrophobic linker is an arylene group or comprises an arylene group and has 6 to 20 carbon atoms. The aryl forming the arylene group includes an aromatic alkyl group (aryl of carbon only) and an aromatic heteroalkyl group (heteroaryl). The former example is phenyl, naphthyl, anthracenyl and phenanthrenyl. Nitrogen-containing heteroaryl preferably should have a pK value of <5 to avoid additional positive charge at neutral pH. Examples of such nitrogen-containing heteroaryl are indolylpyrazinyl, pyridazinyl, pyrimidinyl, cinnolinyl, phthalazinyl and purinyl. The oxygen-containing heteroalkyl group forming the hydroxyl group preferably has pK>12 to avoid having a negative charge at neutral pH.
[0134] Examples of alkylaryl groups are methylphenyl (tolyl), ethylphenyl, 4-isopropylphenyl and xylyl. Examples of arylalkyl (aralkyl) groups are benzyl, phenethyl and trityl. Examples of alkylarylalkyl groups are methylbenzyl and 4-isopropylbenzyl.
[0135] The carboxyarylalkyl moiety may, for example, be a group derived from o-, m- or p-toluic acid, or o-, m- or p-ethylbenzoic acid. The carboxyalkylarylalkyl moiety may, for example, be o-, m- or p-tolueneacetic acid. The carboxyalkenylarylalkyl moiety may, for example, be or be derived from o-, m- or p-methylcinnamic acid.
[0136] The multiple carboxylation substituents present on the polyamine derivatives of the present invention such as those carboxylation substituents that are or comprise carboxylation alkyl groups may be identical or different. For simplicity, they may be identical. The carboxylation group of the carboxylation substituent may be combined with any carbon atom of the hydrophobic linker. Preferably, the carboxylation group is combined with the carbon atom as follows: if z is the number of carbon atoms of the longest carbon chain in the carboxylation substituent (such as carboxylation alkyl group) combined with the carbon atom of the combined polyamine nitrogen atom, if the carbon atom combined with the polyamine nitrogen is recorded as 1, the carboxylation group is combined with the carbon atom at a position more than z / 2 atomic positions away from the polyamine nitrogen. If the value of z / 2 is not an integer, the above-mentioned provisions cause the position to be defined by the next integer of>z / 2. In one embodiment, the carboxylation group is combined with the carbon atom farthest (according to the number of carbon atoms) from the polyamine nitrogen atom that has been connected to the hydrophobic linker (alkylene chain in the case of carboxylation alkyl group). The carboxyl group can be bonded to the carbon atom in the carboxylated substituent (or carboxyalkyl group) that is farthest from the polyamine nitrogen, for example, in the case of a linear carboxylated substituent, the carboxyl group is bonded to the terminal (ω position) carbon atom of the carboxylated substituent (or carboxyalkyl group).
[0137] The possible groups given above for the hydrophobic linker may be substituted, provided that the logP values given above are met. Alternatively, the possible groups given above for the hydrophobic linker may be substituted, provided that the number of carbon atoms and the number of possible heteroatoms as defined above are met.
[0138] Hydrophobic Substituents
[0139] The hydrophobic substituent may be bonded to the amino group of the polyamine and may have a logP of 1.5 to 20, preferably 2 to 15, more preferably 2.5 to 10, which is measured for a compound obtained by replacing the bond of the hydrophobic substituent to the amino group of the polyamine with a bond bonded to a hydrogen atom from the hydrophobic substituent. The method of determining logP is known to those skilled in the art and includes experimentally determining the compound distribution between water and 1-octanol, or obtaining these values from a reference source such as Wikipedia (English version), or calculating logP using software such as ACD / Labs 7.0 (Advanced Chemistry Development, Ontario, Canada).
[0140] The hydrophobic substituent comprises 2 to 40 carbon atoms, comprises 3 to 40 carbon atoms in some aspects, comprises 6 to 40 carbon atoms in preferred aspects, and comprises 6 to 20 carbon atoms in more preferred aspects. In the case where the hydrophobic substituent has 6 or more carbon atoms, the hydrophobic substituent may comprise 1 to 3, preferably 1 or 2 heteroatoms selected from O, N and S. Preferably, the heteroatoms are selected from O and S. Therefore, the hydrophobic substituent may be a hydrocarbyl group or a heterohydrocarbyl group, the latter comprising 1 to 3 heteroatoms as described above. Among the multiple hydrophobic substituents of the polyamine derivative molecule, there may be only a hydrocarbyl group, only a heterohydrocarbyl group, or there may be a hydrocarbyl group and a heterohydrocarbyl group. In one embodiment, a plurality of hydrophobic substituents are all hydrocarbyl groups. In another embodiment, a plurality of hydrophobic substituents are all heterohydrocarbyl groups.
[0141] When the hydrophobic substituent is a hydrocarbyl group, they can be selected from alkyl groups, alkenyl groups, alkynyl groups, cycloalkyl groups, cycloalkenyl groups, cycloalkylalkyl groups, alkylcycloalkyl groups, alkylcycloalkylalkyl groups, aryl groups, alkylaryl groups, arylalkyl groups and alkylarylalkyl groups and groups comprising two or more groups in the above list. In the case where the hydrophobic substituent has 6 or more carbon atoms, oxygen, nitrogen or sulfur, preferably oxygen or sulfur, can be used to replace 1, 2 or 3 carbon atoms in the hydrocarbyl group, thus forming a heteroalkyl substituent. Such heteroalkyl substituents can include a functional group selected from-O-,-S-,-N(H)C(O)-,-C(O)O-,-OC(O)N(H)-,-C(O)-,-C(O)-N(H)-,-N(H)-C(O)-O-,-OC(O)- or-SS-.
[0142] In one aspect of the invention, the hydrophobic substituent is an alkyl group or comprises an alkyl group, such as a straight or branched alkyl group or a cycloalkyl group. The alkyl group can be a normal alkyl group or an isoalkyl group. The example of the alkyl group is propyl, butyl, amyl, hexyl, heptyl, octyl, nonyl, decyl, undecyl, dodecyl, tetradecyl or hexadecyl. The example of the cycloalkyl group is cyclopentyl, cyclohexyl and cycloheptyl.
[0143] Examples of alkenyl groups are propenyl, butenyl, pentenyl, hexenyl, heptenyl, octenyl, nonenyl, decenyl, undecenyl, dodecenyl, tetradecenyl and hexadecenyl. Examples of alkynyl groups are propynyl, butynyl, pentynyl, hexynyl, heptynyl, octynyl, nonynyl, decynyl, undecynyl, dodecynyl, tetradecynyl and hexadecynyl.
[0144] Examples of cycloalkenyl groups are cyclopentenyl, cyclohexenyl and cycloheptenyl.
[0145] Cycloalkylalkyl groups are groups in which a cycloalkyl group is attached to an alkylene group corresponding to the alkyl group. Examples are cyclopentylmethyl, cyclopentylethyl, cyclohexylmethyl, cyclohexylethyl, etc.
[0146] Alkylcycloalkyl groups are groups in which an alkyl group is attached to a cycloalkylene group corresponding to a cycloalkyl group. Examples of alkylcycloalkyl groups are methylcyclopentyl, ethylcyclopentyl, propylcyclopentyl, butylcyclopentyl, pentylcyclopentyl, hexylcyclopentyl, methylcyclohexyl, ethylcyclohexyl, propylcyclohexyl, butylcyclohexyl, pentylcyclohexyl and hexylcyclohexyl.
[0147] An alkylcycloalkylalkyl group is a group in which an alkyl group is attached to a cycloalkylalkylene group.
[0148] In another aspect of the present invention, the hydrophobic substituent comprises an aryl group and has 6 to 20, preferably 7 to 15 carbon atoms. The aryl group includes an aromatic alkyl group (aryl of carbon only) and an aromatic heteroalkyl group (heteroaryl). Examples of the former are phenyl, naphthyl and phenanthrenyl. Nitrogen-containing heteroaryl preferably has a pK value of <5 to avoid carrying an additional positive charge at neutral pH. Examples of such nitrogen-containing heteroaryl are indolylpyrazinyl, pyridazinyl, pyrimidinyl, cinnolinyl, phthalazinyl and purinyl. The oxygen-containing heteroalkyl group forming the hydroxyl group preferably has a pK>12 to avoid carrying a negative charge at neutral pH.
[0149] Examples of alkylaryl groups are methylphenyl (tolyl), ethylphenyl, 4-isopropylphenyl, methylindolyl and xylyl. Examples of arylalkyl (aralkyl) groups are benzyl, phenethyl, indolylmethyl and trityl. Examples of alkylarylalkyl groups are methylbenzyl and 4-isopropylbenzyl.
[0150] The different hydrophobic substituents on the polyamine derivative molecule may be the same or different. For simplicity, they may be the same.
[0151] The possible groups given above for hydrophobic substituents may be substituted, provided that the number of carbon atoms and the number of possible heteroatoms as defined above for substituted hydrophobic substituents is met.
[0152] Preferred polyamine derivatives
[0153] The polyamine derivative of the present invention may be a linear polyalkyleneimine derivative comprising a unit represented by the following formula (10):
[0154] -[CH2-NR 10 -(CH2) x ]- (10)
[0155] in
[0156] x is an integer from 1 to 10, wherein in different (CH2) x The value of x can be the same or different between groups.
[0157] R 10 For hydrogen,
[0158] A carboxylated substituent comprising a carboxylated substituent connected to R via a hydrophobic linker (as defined above) 10 The bound amino nitrogen is bound to the carboxyl group, or
[0159] A hydrophobic substituent as defined above,
[0160] When different R 10 When , they are independently selected from the above groups.
[0161] The number of nitrogen atoms per molecule of the linear polyalkyleneimine or polyamine derivative and the other polyamine part may be from 12 to 100000, preferably from 12 to 20000, more preferably from 20 to 10000, and most preferably from 20 to 5000. 10 Can be the same or different.
[0162] The linear polyamine derivatives defined above by the repeating units of the polymer chain have terminal groups, which are usually formed in the production of the polyamine involved. Therefore, the present invention is not limited to the terminal groups. In the case of linear polyethyleneimine, hydroxyethyl terminal groups may be used. Examples of terminal groups are R defined below: 8 Those.
[0163] Optionally, the polyamine derivative of the present invention is a branched polyalkyleneimine derivative, wherein the branched polyalkyleneimine derivative comprises a unit represented by each of formula (11), formula (12) and formula (13):
[0164] -[CH2-NR 10 -(CH2) x ]- (11)
[0165] -[CH2-NR 11 -(CH2) x ]- (12) and
[0166] -(CH2) y -NR 10 2 (13)
[0167] in
[0168] R 10 and x are as defined above;
[0169] R 11 comprising one or more units selected from formula (11), formula (12) and formula (13);
[0170] y is an integer from 1 to 10, wherein in different (CH2) y The value of y may be the same or different between groups; and
[0171] The number of nitrogen atoms in the linear or branched polyalkyleneimine is 12 to 100,000 per molecule.
[0172] The number of nitrogen atoms per molecule of the branched polyalkylene imine may be as defined above for the linear polyalkylene imine. Examples of terminal groups are R defined below: 8The degree of branching in the branched polyalkyleneimines may be from 1 to 40%, preferably from 10 to 40%, more preferably from 15 to 30%. A person skilled in the art knows how to quantify the branching of a polymer, for example by pH-titration and quantifying the titration curve in different compartments, or by 1H-NMR analysis.
[0173] The combination of carboxylated substituents and hydrophobic substituents in the polyamine derivatives can be characterized by their molar ratio. It was found that the polyamine derivatives of the present invention (such as polyethyleneimine derivatives) perform best if the molar ratio of carboxylated substituents to hydrophobic substituents is from 10:1 to 0.1:1 (C / A ratio). In a preferred embodiment, the C / A ratio of these groups is from 3:1 to 0.33:1.
[0174] When grafted to polyamines, the degree of substitution (DOS) is another relevant characteristic. DOS is defined as the molar percentage of the total number of carboxylated substituents and hydrophobic substituents in each amino group of the polyamine. The DOS is at least 10%, preferably 25 to 80%, more preferably 30 to 60%. Those skilled in the art know how to determine the DOS of polyamine derivatives. This can be achieved, for example, by measuring the residual nitrogen atoms on the polymer using the ninhydrin reaction. Another possibility is to use 1H-NMR spectroscopy.
[0175] In some aspects, the present invention is implemented using a combination of a specific type of carboxylated substituent and a specific type of hydrophobic substituent in each molecule of the polyamine derivative. In these aspects, the total number of carbon atoms of a carboxylated substituent plus the total number of carbon atoms of a hydrophobic substituent is 10 to 30, preferably, the total number is 15 to 25.
[0176] In a further aspect, specific combinations are made between the type of polyamine, the molecular weight of the polyamine, the size of the carboxylated substituent, and the size of the hydrophobic substituent. In a preferred embodiment of this aspect, the polyamine derivative has a linear polyethyleneimine group of 2 to 500 kDa (number average molecular weight), the carboxylated substituent has 11 to 16 carbon atoms and is a normal alkyl carboxylic acid, and the hydrophobic substituent has 3 to 12 carbon atoms and is an alkyl, preferably a normal alkyl or alkyl cyclohexyl.
[0177] In other preferred embodiments, the polyamine derivative has a branched polyethyleneimine group of 0.5 to 200 kDa (number average molecular weight), the carboxylated substituent has 11 to 16 carbon atoms and is a normal alkyl carboxylic acid, and the hydrophobic substituent has 6 to 12 carbon atoms and is an alkyl group, preferably a normal alkyl group or an alkylcyclohexyl group.
[0178] In a further preferred embodiment, the polyamine derivative has a linear polyethyleneimine group of 2 to 500 kDa (number average molecular weight), the carboxylated substituent has 11 to 16 carbon atoms and is an n-alkyl carboxylic acid, and the hydrophobic substituent has 6 to 12 carbon atoms and is an aryl group, preferably selected from an aryl group comprising a benzyl, isopropylbenzyl, naphthyl or indolyl moiety.
[0179] In other preferred embodiments, the polyamine derivative has a branched polyethyleneimine group of 0.5 to 200 kDa (number average molecular weight), the carboxylated substituent has 11 to 16 carbon atoms and is an n-alkyl carboxylic acid group, and the hydrophobic substituent has 6 to 12 carbon atoms and is an aromatic-containing group, preferably selected from a group containing a benzyl, isopropylbenzyl, naphthyl or indolyl moiety.
[0180] In yet other preferred embodiments, the polyamine derivative has a linear oligospermine or oligospermine homologue portion of 1 to 10 kDa (number average molecular weight), the carboxylated substituent has 11 to 16 carbon atoms and is a normal alkyl carboxylic acid group, and the hydrophobic substituent has 4 to 10 carbon atoms and is an alkyl group, preferably a normal alkyl group.
[0181] In one embodiment, the polyamine derivatives of the present invention are carboxyalkyl-alkyl polyamines. The alkyl moiety contains at least 2 carbon atoms. In some aspects of the present invention, the alkyl moiety has 3 to 40 carbon atoms. In a preferred aspect, the alkyl moiety is a straight chain alkyl with 6 to 40 carbon atoms, and in a more preferred aspect, the number of carbon atoms is 6 to 20. The multiple alkyl groups present on the polyamines may be the same or different. In other aspects of the present invention, the alkyl moiety also contains an aromatic ring and has 6 to 40 carbon atoms.
[0182] Carboxyalkyl-alkyl-polyamine
[0183] The carboxyalkyl-alkyl-polyamine may be a linear carboxyalkyl-alkyl-polyalkyleneimine comprising or consisting essentially of units represented by formula (6):
[0184] -[CH2-NR 6 -(CH2) x ]- (6),
[0185] wherein x is an integer from 1 to 10, wherein in different (CH2) x The value of x can be the same or different between groups; R 6 is hydrogen, formula C r H 2r+1 The alkyl group shown or the formula C s-1 H 2s-2The carboxyalkyl group represented by COOH. Different R 6 , it is independently selected from the above groups; r is an integer from 2 to 40 and s is an integer from 4 to 40. Preferred embodiments for x are as defined below in the case of formula (1). The number r is preferably from 6 to 40, more preferably from 6 to 20. The number s is preferably from 4 to 20, more preferably from 6 to 20, and even more preferably from 8 to 16.
[0186] The number of nitrogen atoms per molecule of the linear carboxyalkyl-alkyl-polyalkyleneimine may be 12 to 100,000, preferably 12 to 20,000, more preferably 20 to 10,000, and most preferably 20 to 5,000.
[0187] The linear carboxyalkyl-alkyl-polyamines as defined above by the polymer chain repeating units have terminal groups as generally formed in the production of the underlying polyamine. Thus, the present invention is not limited to the terminal groups. Examples of terminal groups are R defined below: 8 Those.
[0188] Optionally, the carboxyalkyl-alkyl-polyamine is a branched carboxyalkyl-alkyl-polyalkyleneimine. The branched carboxyalkyl-alkyl-polyalkyleneimine may comprise a structural unit represented by each of formula (7), formula (8) and formula (9):
[0189] -[CH2-NR 6 -(CH2) x ]- (7)
[0190] -[CH2-NR 7 -(CH2) x ]- (8)
[0191] -(CH) y -NR 6 2 (9)
[0192] in
[0193] R 6 , x, r and s are as defined above;
[0194] R 7 comprising one or more structures selected from formula (7), formula (8) and formula (9);
[0195] y is an integer from 1 to 10, preferably an integer from 2 to 10, more preferably an integer from 2 to 6, wherein at different occurrences of (CH2) y The values of y in the groups may be the same or different.
[0196] R 7It can be a group represented by formula (9) or R 7 Contains one or more units represented by formula (7) and / or formula (8). 7 It is also possible to contain one or more units represented by formula (7) and one or more units represented by formula (8). Since carboxyalkyl-alkyl-polyalkyleneimine is polymeric, one molecule thereof usually contains a plurality of groups R having different structures. 7 .
[0197] The number of nitrogen atoms per molecule of the branched carboxyalkyl-alkyl-polyalkyleneimine is from 12 to 100,000, preferably from 20 to 20,000, more preferably from 20 to 10,000, and most preferably from 20 to 5,000.
[0198] The degree of branching in the branched polyalkyleneimines may be from 1 to 40%, preferably from 10 to 40%, more preferably from 15 to 30%. A person skilled in the art knows how to quantify the branching of a polymer, for example by pH-titration and quantifying the titration curve in different compartments.
[0199] The molar ratio of carboxyalkyl to alkyl in the above carboxyalkyl-alkyl-polyalkyleneimine can be defined as follows. The degree of substitution (DOS) can also be defined as follows.
[0200] In some aspects, specific combinations of carboxyalkyl and alkyl moieties are employed to implement the invention utilizing carboxyalkyl-alkyl-polyalkyleneimines. In preferred embodiments, the carboxyalkyl group is combined with an aliphatic alkyl group and the total number of carbon atoms in the two moieties is from 10 to 30, and in more preferred embodiments, the total number is from 15 to 20. In these embodiments, one type of carboxyalkyl group is preferably combined with one type of alkyl group.
[0201] In a further aspect, specific combinations are made between the polyamine type, the polyamine molecular weight, the length of the carboxyalkyl group, and the length of the alkyl group. In a more preferred embodiment of this aspect, the polyamine is a straight-chain polyethyleneimine with 2 to 30 kDa (number average molecular weight), the carboxyalkyl group has 8 to 16 carbon atoms and the alkyl has 6 to 16 carbon atoms. More preferably, the combination wherein the carboxyalkyl group has 10 to 16 carbon atoms and the alkyl has about 9 carbon atoms. In another preferred embodiment, the polyethyleneimine is a side-chain polymer with about 10 kDa, the carboxyalkyl group has 8 to 16 carbon atoms and the alkyl has 6 to 16 carbon atoms, more preferably about 9 carbon atoms.
[0202] The combination of carboxyalkyl and alkyl groups in the carboxyalkyl-alkyl-polyamines can be characterized by their molar ratio. It has been found that the carboxyalkyl-alkyl-polyamines of the present invention (such as carboxyalkyl-alkyl-polyethyleneimine) perform best if the molar ratio of the carboxyalkyl moiety to the alkyl moiety is from 6:1 to 0.33:1 (C / A ratio). In a preferred embodiment, the C / A ratio of these groups is from 3:1 to 0.8:1. In a more preferred embodiment, the polyamine is a polyethyleneimine substituted with C11 carboxyalkyl groups and C9 alkyl groups, wherein the C / A ratio is from 2:1 to 0.5:1, more preferably about 1.
[0203] When grafted to a polymer, the degree of substitution (DOS) is another relevant characteristic. DOS is defined as the molar percentage of the sum of the carboxyalkyl moieties and the alkyl moieties in each amino group of the polyamine. The DOS is at least 10%, preferably 25 to 80%, more preferably 30 to 60%. Those skilled in the art know how to determine the DOS of a polyamine derivative. This can be achieved by measuring the residual nitrogen atoms on the polymer, for example using the ninhydrin reaction. Another possible method is to use 1H-NMR spectroscopy.
[0204] In a particularly preferred embodiment, the polyamine is a polyethyleneimine substituted with C11 carboxylic acid and C9 alkyl groups, wherein the C / A ratio is 2:1 to 0.5:1, and the DOS is 35 to 45%.
[0205] Table 3 below lists some specific embodiments of polyamine derivatives. See Examples 11 and 15 for a list of abbreviations or symbol names.
[0206] Table 3
[0207]
[0208]
[0209] Throughout the specification of this application, structural formulae are given in an uncharged or non-ionized form. However, it will be apparent to those skilled in the art that the nitrogen atoms of these structures may be protonated, particularly in aqueous solution. Therefore, compounds defined by any of these formulae also include compounds or ions in which any of the nitrogen atoms is in a charged state.
[0210] Production of polyamine derivatives
[0211] The above-mentioned carboxylated substituents and hydrophobic substituents can be used to modify any of the above-mentioned polyamines to prepare the polyamine derivatives of the present invention. These methods are well known in the art and are further described in the examples. For example, by using halocarboxylic acids and halogenated hydrophobic compounds to derivatize polyamines under alkaline conditions, carboxylated substituents and hydrophobic substituents are introduced via their corresponding halogenated compounds. Bromine is preferably used as the halogen atom in these compounds. In a preferred embodiment, this is achieved by using α, ω-bromocarboxylic acids and bromo compounds such as brominated alkanes or bromoaryl compounds as halogenated compounds. The two derivatizations can be carried out continuously or in parallel using a mixture of halocarboxylic acids and halogenated hydrophobic compounds. The mixing ratio of halocarboxylic acids and halogenated hydrophobic compounds is appropriately selected to achieve the desired molar ratio of carboxyl and hydrophobic groups in the polyamine derivatives to be prepared. Approximately, the molar mixing ratio of halocarboxylic acids and halogenated hydrophobic compounds in the parallel modification reaction corresponds to the molar ratio of carboxylated substituents and hydrophobic substituents in the polyamine derivatives. The mol ratio of carboxylated substituent and hydrophobic part in the obtained product can be analyzed, for example, by 1H-NMR. The mixing ratio of halocarboxylic acid and halogenated hydrophobic compound can be adjusted by the deviation between the measured mol ratio and the desired mol ratio, so as to obtain the modified polyamines substituted by these substituents of the desired mol ratio. It is obvious to those skilled in the art that the desired degree of substitution (DOS) can be reached and if necessary, the molar amount of suitable halocarboxylic acid and halogenated hydrophobic compound relative to the amount of polyamines can be adjusted in a similar manner. The reaction is usually carried out in an organic solvent, preferably a polar organic solvent such as ethanol. In other embodiments, the introduction of carboxylated substituent and hydrophobic substituent is realized by acylation using corresponding dicarboxylic acid, their anhydride or chloride or by Michael-addition using unsaturated derivatives of carboxylic acid and halogenated hydrophobic compound respectively.
[0212] The polyamine derivatives of the present invention are different from the compounds described in the prior art. Wakefield et al. (2005) Bioconj Chem 16 (5): 1204-1208 reported copolymers of aminoethyl-vinyl ethers and alkyl-vinyl ethers having alkyl groups of 1 to 4 carbon atoms. In contrast to the present invention, Wakefield's polymers do not contain carboxyl groups, and thus lack the necessary type of functional groups on the polymer. The polyamine derivatives of the present invention are also different from the modified polyethyleneimines presented by van Vliet et al. (2008) in Chembiochem, 2008, 9, 1960-1967. There, polyethyleneimines were systematically modified using dodecyl, benzyl and methyl moieties. Likewise, the necessary carboxylalkyl groups of the present invention were not applied in van Vliet. In addition, quaternized amino groups were extensively formed by using methyl iodide.
[0213] In contrast to Wakefield or van Vliet, neither WO08 / 074488 nor Oskuee et al. (2010) J Gene Med 12: 729-738 mention the use of additional alkyl groups. In fact, WO08 / 074488 explicitly distinguishes between the use of carboxyalkyl groups (TEE's therein) and the mere hydrophobic modification achieved by alkylation (page 60 of the A2 document). On the other hand, Oskuee teaches that the effect of carboxylation is mediated by reducing the surface charge (a feature not mediated by alkylation).
[0214] Use of the polyamine derivatives of the present invention as transfection agents
[0215] The polyamine derivatives of the present invention, such as carboxyalkyl-alkyl-polyamines, are used to transfect polyanions into cells, and therefore, these polyamine derivatives are also referred to herein as transfection agents of the present invention.
[0216] The polyanion can be selected from the group of peptides, proteins and nucleic acids. In some embodiments, the polyanion is a protein selected from an antibody. In a specific embodiment, the antibody is an IgG type. In other embodiments, an antibody fragment is used, such as a F(ab')2 fragment of Fab, Fab', a disulfide connection or a chemically connected F(ab')2 fragment or a scFv fragment. In a preferred embodiment, the polyanion is a nucleic acid.
[0217] Nucleic acid used herein is a polynucleotide or oligonucleotide, including but not limited to DNA or RNA or its derivatives or analogs. Polynucleotide used herein refers to any polyribonucleotide or polydeoxyribonucleotide, which can be unmodified RNA or DNA, or modified RNA or DNA, or mixed DNA / RNA. Polynucleotide can be single-stranded or double-stranded. An example of double-stranded polynucleotide is plasmid, and an example of single-stranded polynucleotide is mRNA. Oligonucleotide used herein is defined as a molecule with two or more, usually more than three, and usually more than 10 but less than 100 nucleotides, which can be unmodified RNA or DNA, or mixed DNA / RNA, or modified RNA or DNA, wherein the modification includes, for example, various modifications such as 2'Me, 2'OMe, 2'MOE, 2'F, etc., of the 2' position of the ring bridge, nucleoside, or wherein using sugars other than ribose, such as arabinose in 2'FANA nucleotides, glycerol in unlocking nucleic acids or hexitol structures. The size of the oligonucleotide can depend on many factors, including the final use of the oligonucleotide. Typical examples of oligonucleotides are siRNA, antisense inhibitors, miRNA, DNA enzymes, aptamers, etc. Basically, all nucleic acids that carry a negative charge on their backbone can be used compatible with the transfection agent of the present invention, including various backbone-modified nucleic acids, such as those containing thiophosphate bonds or dithiophosphate bonds. In contrast, uncharged nucleic acids such as those constructed from methylphosphonates or peptide-nucleic acids (PNA's) are not very compatible with the transfection agent of the present invention.
[0218] For transfection of nucleic acid or other polyanions, a complex between nucleic acid (or other polyanions) and a transfection agent is usually made. The formation of a complex between a transfection agent and a polyanion is well known to those skilled in the art. Usually, this can be achieved by combining a first solution comprising a transfection agent with a second solution comprising a polyanion or nucleic acid. Usually, the number of positive charges provided by the transfection agent is higher than the number of negative charges on the polyanion. This ratio is referred to as the N / P ratio in the art, where N represents the number of formal nitrogen charges on the transfection agent and P represents the number of phosphate groups on the nucleic acid. In some embodiments, the N / P ratio used in combination with polyamine derivatives and nucleic acids is 2 to 20. In a preferred embodiment, the ratio is 5 to 15, and in a more preferred embodiment, the N / P ratio is about 10.
[0219] In other embodiments, the N / P ratio is 2 to 6, more preferably about 4. Depending on the N / P ratio, the complex between the nucleic acid and the polyamine derivative can have different charges and different particle sizes. As determined by zeta potential measurement, complexes with N / P values of about 10 or more have a neutral or slightly positive surface charge. As determined by dynamic light scattering, the particle size of such complexes is 200 to 1000 nm, and in a preferred embodiment is 250 to 500 nm.
[0220] As determined by zeta potential measurements, complexes with N / P of about 6 or less have a neutral or negative surface charge. As determined by dynamic light scattering, complexes with N / P of about 6 or less have a particle size of 50 to 500 nm, and in preferred embodiments 100 to 200 nm.
[0221] The particle size and surface charge of the particles are determinants of particle distribution in the systemic circulation of a vertebrate, mammal or human, as is well known to those skilled in the art. Particles of 150 nm or less in size are able to reach the liver parenchyma from the bloodstream, while large particles are excluded. In contrast, larger particles up to about 500 nm can reach tumors, sites of inflammation or stromal cells in the spleen.
[0222] The complex formation between the transfection agent of the present invention and the polyanion to be transfected is usually carried out. The complex formation between polyanions such as nucleic acids involves charge interaction with the transfection agent. This interaction is realized in an aqueous solution with a pH range between 3 and 9, wherein both complex partners are ionized. The pH used for complex formation in some embodiments is 4 to 8, and in a preferred embodiment the pH is 5 to 7. The pH of the complex formation solution is adjusted by using one or more buffer substances. In principle, any buffer substance with a pK in the above range and non-toxic to cells can be used. In a preferred embodiment, a buffer based on acetate, maleate, succinate, carbonate, phosphate, citrate, methyl ethyl sulfonate (MES), Bis-Tris, Bis-Tris-propane, tris-(hydroxymethyl)aminomethane (tris-(hydroxymethyl)aminomethan), a zwitterionic buffer (tricine) or a buffer such as the Good series of HEPES, TES, MOPS, BES, MOPSO, ACES, PIPES, ADA, HEPPS is used. More preferred buffers are acetate, phosphate, citrate or HEPES.
[0223] The solution in which complex formation occurs may contain other ingredients, such as salts or sugars, as long as these substances do not antagonize complex formation or are not toxic to cells. In a preferred embodiment, the amount of salt is limited so that the total ionic strength of the solution is less than 0.2 mol / L, and in a more preferred embodiment the ionic strength is less than 0.1 mol / L. A salt well tolerated by cells is sodium chloride. For the binding of oligonucleotides, low ionic strengths of less than 0.1 mol / L are preferred, while for complex formation using polynucleotides such as plasmids or mRNA, the ionic strength can be higher.
[0224] To avoid osmotic stress during the addition of transfection complexes to cells, sugars can be added to the complex formation solution to adjust the osmotic pressure. In some embodiments, the addition of sugars is limited so that the total osmotic pressure of the solution added to the cells is 150 to 500 mosm / L, and in preferred embodiments, the osmotic pressure is 270 to 310 mosm / L. In preferred embodiments, glucose, sucrose or trehalose are used to adjust the osmotic pressure of the transfection mixture.
[0225] Surprisingly, it was found that certain media with unknown composition can also be used to prepare the transfection mixture.In many cases, cell culture media such as DMEM, Optimem (trademark of Life Technologies) and the like can be used to prepare the transfection mixture.
[0226] The transfection agent of the present invention may have limited solubility in water or buffered solutions. Solubility is a function of pH and the concomitant ionization of the polyamine derivatives of the present invention. As a general rule, these compounds have better solubility in acidified water (e.g., in a medium with a pH of 7 or lower). In contrast, polyamine derivatives are readily soluble in alcohols such as ethanol, propanol, 1,2-dihydroxypropane or isopropanol (these are also collectively referred to herein as "short-chain alcohols") at a pH of 9 or higher. Depending on the pH, mixtures of short-chain alcohols and water can also be used as solvents, such as mixtures containing 33 to 100% ethanol, propanol, 1,2-dihydroxypropane or isopropanol for less ionized forms of the transfection agent, or mixtures containing 0 to 66% of the alcohols for more ionized forms of the transfection agent. In certain embodiments, the transfection agent is stored as a stock solution of the transfection agent containing 20 to 200 mM (based on nitrogen atoms in the transfection agent) in a lower alcohol such as a short-chain alcohol. Working concentrations of about 0.1 mM to 5 mM of the transfection agent can then be generated by diluting the stock solution into an aqueous buffer solution. Generally, short chain alcohols do not need to be removed from the transfection mixture and are tolerated by the cells.
[0227] In a specific embodiment, the transfection agent is used according to the following transfection protocol:
[0228] 1) The polyamine derivative is provided as a 50 mM solution (based on nitrogen content) in 33 to 100% ethanol, preferably 70% ethanol.
[0229] 2) Prepare transfection buffer containing 10 mM sodium dihydrogen phosphate and 3 mM sodium hydroxide.
[0230] 3) Dilute the modified polyamine to a 1 mM solution in transfection buffer.
[0231] 4) Dilute siRNA to 22 μM siRNA in transfection buffer. Since the average number of phosphate groups on siRNA is about 45, the total concentration of phosphorus is about 1 mM.
[0232] 5) The working solutions of polyamine and siRNA were combined in a 10+1 ratio, so that the N / P ratio was 10 and the concentration of siRNA in the complexation mixture was 2 μM.
[0233] 6) Add up to 20 μl of the transfection mixture prepared in (5) per 100 μl of the medium in which the cells were cultured.
[0234] In an alternative embodiment, the transfection agent is used using the following general protocol:
[0235] 1) The polyamine derivative is provided as a 50 mM solution (based on monomer weight) in 33 to 100%, preferably 70%, ethanol.
[0236] 2) Prepare transfection buffer containing 10 mM citric acid and 19 mM sodium hydroxide.
[0237] 3) Dilute the modified polyamine to a 1.8 mM solution in transfection buffer.
[0238] 4) Dilute siRNA to 4 μM siRNA in transfection buffer.
[0239] 5) The working solutions of polyamine and siRNA were combined in a 1+1 ratio, so that the N / P ratio was about 10 and the concentration of siRNA during complexation was 2 μM.
[0240] 6) Add up to 20 μl of the transfection mixture prepared in (5) per 100 μl of the medium in which the cells were cultured.
[0241] The following general protocol 3 can be used to prepare transfection agents with small particle size:
[0242] 1) The polyamine derivative is provided as a 56 mM solution (based on nitrogen content) in 33 to 100% ethanol, preferably 70% ethanol.
[0243] 2) Prepare transfection buffer containing 10 mM sodium dihydrogen phosphate and 3 mM sodium hydroxide.
[0244] 3) Dilute siRNA to 18 μM siRNA in transfection buffer. Since the average number of phosphate groups on siRNA is about 45, the total concentration of phosphorus is about 0.75 mM
[0245] 4) The siRNA solution was added directly to the modified polyamine at a ratio of 20+1, resulting in an N / P ratio of 4 and a siRNA concentration of 17 μM in the complex mixture.
[0246] 5) Add up to 10 μl of the transfection mixture to every 100 μl of medium in which cells are cultured or administer to animals.
[0247] Although it is often done to prepare transfection complexes from two solutions, it is necessary to prepare solutions containing the transfection agent and the nucleic acid separately. In order for it to work in cell culture, the solutions need to be clean or sterile; they may also have a limited shelf life. A further improvement is the use of a dry transfection agent that is reconstituted with a transfection buffer before use. To achieve this goal, the transfection agent can be dried from its solution in a short-chain alcohol. A particular benefit of this method is that small and aliquoted transfection agents are provided with a very long shelf life. The dry transfection agent can be rehydrated with a transfection buffer. In some embodiments, the dry transfection agent can also be rehydrated with a solution that already contains nucleic acids.
[0248] In other embodiments, the transfection agent is provided in a lyophilized form. In a preferred aspect of this embodiment, the transfection agent is lyophilized from a solution comprising a buffer system adjusted to a pH between 5 and 7 and further comprising an amount of sugar to obtain a total osmotic pressure of 100 to 500 mosm / L during reconstitution, such as 270 mM sucrose or trehalose or glucose. In this embodiment, the nucleic acid is provided in a dilute aqueous solution and is directly used for the reconstitution of the lyophilized transfection agent so that hydration and complex formation occur in a single step. The resulting transfection mixture can then be added directly to the cells to be transfected.
[0249] The transfection agent of the present invention can be sold on the market in the form of a kit, which optionally further comprises siRNA for controlling the reaction.
[0250] In a first embodiment, the kit comprises the following:
[0251] A) a solution of a transfection agent in a short chain alcohol, wherein the alcohol may be 70% ethanol and the transfection agent may have a concentration of about 50 mM (based on nitrogen atoms in the transfection agent),
[0252] B) a buffer solution having a pH value between 4 and 8 and an ionic strength below 0.2, preferably below 0.1,
[0253] C) A manual with complete instructions for use, optionally a short manual with brief instructions for use.
[0254] In a second embodiment, the kit comprises the following:
[0255] A) A transfection agent solution as described in the first embodiment, wherein the solution is divided into aliquots. Preferably, the number of aliquots is 5 to 100, more preferably the number of aliquots is 6 to 20. It is further preferred that each aliquot contains 10 to 1000 nmol of transfection agent (based on monomers),
[0256] B) a buffer solution having a pH value between 4 and 8 and an ionic strength below 0.2, preferably below 0.1,
[0257] C) A manual with complete instructions for use, optionally a short manual with brief instructions for use.
[0258] In a third embodiment, the kit comprises the following:
[0259] A) a transfection agent solution as described in the first embodiment, wherein the solution is divided into aliquots, and wherein the aliquots are arranged in a microplate having 6 to 1576 wells, preferably 24, 96 or 384 wells, and wherein each aliquot contains 10 to 1000 nmol of the transfection agent,
[0260] B) a buffer solution having a pH value between 4 and 8 and an ionic strength below 0.2, preferably below 0.1,
[0261] C) A manual with complete instructions for use, optionally a short manual with brief instructions for use.
[0262] In a fourth embodiment, the kit comprises the following:
[0263] A) dry transfection agent divided into aliquots. Preferably, the number of aliquots is from 5 to 100, more preferably the number of aliquots is from 6 to 20. It is further preferred that each aliquot contains 10 to 1000 nmol of transfection agent (based on monomers),
[0264] B) a buffer solution having a pH value between 4 and 8 and an ionic strength below 0.2, preferably below 0.1,
[0265] C) A manual with complete instructions for use, optionally a short manual with brief instructions for use.
[0266] In a fifth embodiment, the kit comprises the following:
[0267] A) a dry transfection agent divided into aliquots, wherein the aliquots are arranged in a microplate having 6 to 1576 wells, preferably a microplate having 24, 96 or 384 wells, and wherein each aliquot contains 10 to 1000 nmol of the transfection agent,
[0268] B) a buffer solution having a pH value between 4 and 8 and an ionic strength below 0.2, preferably below 0.1,
[0269] C) A manual with complete instructions for use, optionally a short manual with brief instructions for use.
[0270] In a sixth embodiment, the kit comprises the following:
[0271] A) Lyophilized transfection agent divided into aliquots. Preferably, the number of aliquots is 5 to 100, more preferably the number of aliquots is 6 to 20. It is further preferred that each aliquot contains 10 to 1000 nmol transfection agent (based on monomers),
[0272] B) a buffer solution having a pH value between 4 and 8 and an ionic strength below 0.2, preferably below 0.1,
[0273] C) A manual with complete instructions for use, optionally a short manual with brief instructions for use.
[0274] In a seventh embodiment, the kit comprises the following:
[0275] A) Lyophilized transfection agent divided into aliquots, wherein the aliquots are arranged in a microplate having 6 to 1576 wells, preferably 24, 96 or 384 wells, and wherein each aliquot contains 10 to 1000 nmol of transfection agent
[0276] B) a buffer solution having a pH value between 4 and 8 and an ionic strength below 0.2, preferably below 0.1,
[0277] C) A manual with complete instructions for use, optionally a short manual with brief instructions for use.
[0278] In certain aspects of the third, fifth and seventh embodiments, all wells of the microplate contain the same amount of transfection agent. In other aspects, the wells contain different amounts of transfection agent. Such a design can involve a gradient of transfection agent in adjacent wells, which is very useful in optimizing the N / P ratio with nucleic acids. In other aspects, some wells can be empty, for example, for generating a series of dilutions from a complex mixture. Figures 1 to 4 Such a design is further described with arrayed amounts of transfection agents, for example, in a 96-well plate.
[0279] In some other embodiments, the compound of polyamine derivatives of the present invention and one or more nucleic acids is formed and lyophilized and sold on the market as a complete product. Relative to current commercial products, this solution provides a higher degree of integration. It also provides the opportunity to centralize the quality control of the product including its particle formation on the manufacturer's site. Other advantages of the lyophilized compound are their long-term storage stability and the solvent that does not use short-chain alcohol as modified polyamines.
[0280] The lyophilized complex between the polyamine derivative and one or more nucleic acids has particular advantages for use in in vivo applications including animal studies or for therapeutic use.
[0281] The lyophilized complex can be produced using any of the general methods 1 to 3 described above including lyophilization and rehydration steps after complexation.
[0282] In a specific embodiment, the complex between the modified polyamine of the present invention and one or more nucleic acids is prepared according to the following Scheme 4:
[0283] 1) Provide the modified polyamine as a 50 mM solution (based on nitrogen content) in 33 to 100% ethanol
[0284] 2) Prepare transfection buffer containing 10 mM sodium dihydrogen phosphate and 3 mM sodium hydroxide.
[0285] 3) Dilute the modified polyamine to a 1 mM solution in transfection buffer.
[0286] 4) Dilute siRNA to 22 μM siRNA in transfection buffer. Since the average number of phosphate groups on siRNA is about 45, the total concentration of phosphorus is about 1 mM.
[0287] 5) The working solutions of polyamine and siRNA were combined in a 10+1 ratio, so that the N / P ratio was 10 and the concentration of siRNA in the complex mixture was 2 μM.
[0288] 6) The complex is optionally divided into aliquots, lyophilized, hermetically sealed and stored.
[0289] 7) Rehydrate the lyophilized complex with water.
[0290] 8) Add up to 20 μl of the rehydrated complex per 100 μl of medium used to culture cells or administer the rehydrated complex to animals or humans.
[0291] In a specific embodiment, the complex between the modified polyamine of the present invention and one or more nucleic acids is prepared according to the following Scheme 5:
[0292] 1) The modified polyamine was provided as a 56 mM solution (based on nitrogen content) in 33 to 100% ethanol.
[0293] 2) Prepare transfection buffer containing 10 mM sodium dihydrogen phosphate and 3 mM sodium hydroxide.
[0294] 3) Dilute siRNA to 18 μM siRNA in transfection buffer. Since the average number of phosphate groups on siRNA is about 45, the total concentration of phosphorus is about 0.75 mM.
[0295] 4) The siRNA solution was added directly to the modified polyamine at a ratio of 20+1, resulting in an N / P ratio of 4 and a siRNA concentration of 17 μM in the complex mixture.
[0296] 5) The complex is optionally divided into aliquots, lyophilized, hermetically sealed and stored.
[0297] 6) Rehydrate the lyophilized complex with water.
[0298] 7) Add up to 10 μl of the rehydrated complex per 100 μl of medium used to culture cells or administer the rehydrated complex to animals or humans.
[0299] The administration of the composite nucleic acid to animals or humans is well known to those skilled in the art, and the composite nucleic acid can be administered systemically or locally at the dosage required for the specific indication. The amount of nucleic acid administered can vary between 0.1 μg and 100 mg per kg body weight, and can be administered once or multiple times or in a complex or intermittent dosing regimen, such as daily dosing, every other day or three times a week, once a week or once a month, or a combination of these regimens. BRIEF DESCRIPTION OF THE DRAWINGS
[0300] Figure 1-Figure 4 : The accompanying drawings show various schemes for arranging transfectants in a microplate. The numbers in the schematic microplate represent the amount of transfectant placed in each well, expressed in nmol (based on nitrogen atoms). The accompanying drawings use a 96-well plate as an example, and place the transfectants in certain vertical rows. It will be appreciated that similar schemes can be easily derived from this general structure, for example, where the pattern is organized horizontally, utilizing more or fewer empty wells, locally applying the plate, and the like.
[0301] Figure 1 , the amount of transfection agent placed in certain wells of a 96-well plate, expressed in nmol, evenly distributed.
[0302] Figure 2 , the amount of transfection reagent placed in certain wells of a 96-well plate, expressed in nmol, to simplify optimization of the N / P ratio.
[0303] Figure 3 , the amount of transfection agent placed in certain wells of the microplate, expressed in nmol, including empty wells used for serial dilutions of transfection complexes.
[0304] Figure 4 , the amount of transfection agent placed in certain wells of the microplate, expressed in nmol, facilitates simple optimization of the N / P ratio and serial dilutions of the transfection complexes. Example
[0305] The present invention will now be further illustrated by the following examples, but is not limited thereto.
[0306] Example 1 - Modification of polyamines
[0307] Linear PEI (free base) with an average molecular mass of 2 kDa or 25 kDa was obtained from Polysciences, catalog items 24313 and 23966, respectively. Branched PEI (free base) with a size of 10 kDa was obtained from Aldrich, catalog item 408727. The polymer was dissolved in anhydrous ethanol at a concentration of 250 mono-mM; that is, the concentration of nitrogen was 250 mM. Propyl bromide, hexyl bromide, nonyl bromide and dodecyl bromide (all from SIGMA) were dissolved in anhydrous ethanol at a concentration of 250 mM, and methyl 3-bromopropionate, methyl 6-bromohexanoate, ethyl 8-bromooctanoate, methyl 11-bromodencanoate or methyl 16-bromodehexadecanoate was dissolved in anhydrous ethanol at a concentration of 500 mM. K2CO3 was used as a 6 M aqueous solution.
[0308] For modification of 100 μmol of polyamine (based on monomer), pipette the following solutions per reaction:
[0309] -400 μl polyamine solution
[0310] -X μl ω-bromocarboxylate
[0311] -Y μl 1-bromoalkane
[0312] - Up to 650 μl of ethanol (wthanol)
[0313] -33 μl K2CO3
[0314] All mixtures were sealed and incubated in an oven at 60°C for 7 days. Afterwards, 250 μl of 2N NaOH was added, the mixtures were sealed again and incubated at 60°C for another 2 days. For the initial tests, a small aliquot of the reaction mixture was taken and diluted 1:100 in 75% ethanol / water. 42 μl of each diluted sample was transferred to a 96-well plate and dried.
[0315] Example 2 Complex with siRNA
[0316] The modified polyamine was hydrated in 50 μl buffer pH 4 (10 mM HAc, 10 mM NaH2PO4, pH 4 adjusted with NaOH) for 20 min. 50 μl of siRNA (2 μM in buffer pH 4) was added and after 2-3 min the polymer-siRNA solution was brought to pH 7 using 10 μl of 160 mM NaOH.
[0317] Example 3 - Cultivation of cells
[0318] HeLa cells were cultured in 100 μl RPMI1640 medium (PAA Lab GmbH) supplemented with 10% FCS (Sigma-Aldrich), 1x Pen / Strep (PAA lab GmbH) solution (according to the manufacturer's instructions) and seeded in 96-well plates at a density of 4000 cells / well. The density of viable cells was measured using a Countess Cell counter (Invitrogen). Cells were cultured in a humidified incubator at 37°C and 5% CO2. 24 hours after plating, cells were provided with fresh complete medium and transfected on the same day.
[0319] Example 4 - Transfection of cells
[0320] HeLa cells were transfected with polyamine-siRNA complexes by transferring 10 μl per well of the material obtained according to Example 2. As a result of this addition, the concentration of PLK-1 siRNA in the cell culture medium was 100 nM. Without changing the culture medium, the cells were cultured for 3 days at 37° C. and 5% CO2 in a humidified incubator.
[0321] Example 5 - Types of siRNA
[0322] The siRNA used in this article targets the PLK-1 gene, whose product is an important component of the cell cycle. Downregulation of the target protein leads to mitotic arrest and apoptosis. Therefore, cell viability assays are used to monitor cell transfection. The siRNA targeting PLK-1 and an unrelated control siRNA used in this article were published by Haupenthal et al. (2007) Int J Cancer, 121, 206-210.
[0323] Example 6 - Vitality Detection
[0324] After 3 days, the cells were tested for care by using Cell Titer Blue assay (CTB, Promega). The culture medium was discarded and the cells were provided with fresh complete culture medium supplemented with CTB reagent (5:1, vol / vol). After incubation for 90-100 minutes at 37°C and 5% CO2 in a humidified incubator, the samples were transferred to a black fluorescent plate and the color change of the samples was measured by a fluorescence reader at Ex560nm / Em590nm. The signal was normalized to 100% using untreated cells grown on the same culture plate and to 0% using wells without inoculated cells.
[0325] Example 7 - Transfection using modified polyamines
[0326] The following table shows the % of viable cells relative to untreated cultures as a measure of PLK-1 downregulation after cell transfection. In the experiments, carboxylated polyamines, alkylated polyamines and co-modified polyamines were tested in parallel.
[0327] Table 4 – Transfection using carboxylated polyethyleneimine
[0328]
[0329]
[0330] 1 ) Equivalent value of ω-bromo-carboxylic acid methyl ester per nitrogen addition of PEI polymer
[0331] Table 5 – Transfection using alkylated polyethyleneimine
[0332]
[0333] 2 ) The equivalent value of ω-bromoalkane added per nitrogen in PEI polymer
[0334] Table 6 – Transfection using combined modified polyethyleneimine
[0335]
[0336] 3 ) The combined equivalents of ω-bromo-undecanoic acid methyl ester and 1-bromoalkane per nitrogen addition of the PEI polymer, with a ratio of ω-bromocarboxylic acid to bromoalkane of 1.25:1
[0337] Polyethyleneimine used herein was essentially an inactive transfection agent under the assay conditions, with only branched PEI showing weak activity. Certain single modifications using either the alkyl or carboxyl moieties resulted in improved activity and reduced cell viability by less than 50% as highlighted in the table. Combined modifications using both carboxyalkyl and alkyl moieties showed much greater activity against cells, and the improvement was evident over a wide range of DOS.
[0338] Example 8 - Transfection efficiency in different cell types
[0339] Transfection reagents: 5 mmol of branched PEI was modified with 11-bromondecanoic acid methyl ester and nonyl bromide as described in Example 1, and all other reagents were scaled in equal proportions. The degree of substitution was about 40%, and the ratio between the modifiers was about 1. The modified Pei was purified from the reaction mixture by size exclusion chromatography in 10 mM NaOH, 70% ethanol.
[0340] Complexation: The purified transfection agent was provided in a solution containing 30% ethanol and 10 mM NaOH. The polymer was diluted to a concentration of 4 mM in buffer D (10 mM citrate, adjusted to pH 5.0 with NaOH) or buffer F (10 mM phosphate, adjusted to pH 6.5 with NaOH). To obtain an NP-ratio of 10, 150 μl of the diluted polymer was complexed with 150 μl of a 10 μM siRNA solution (Plk1 or negative control (scrambled control)) in buffer D or F. Serial dilutions of these mixtures were performed in the respective buffers in 96-well plates to obtain concentrations of 500 nM to 2 nM on the cells.
[0341] Transfection: Cells were transfected with polymer-siRNA-complexes by transferring 10 μl / well from the "complex plate" to the cell plate (columns 1-10). Without changing the medium, cells were cultured for 3 days at 37°C and 5% CO2 in a humidified incubator.
[0342] Viability detection: After 3 days, the viability of the cells was tested by using Cell Titer Blue assay (CTB, Promega). The culture medium was discarded and the cells were provided with fresh complete culture medium supplemented with CTB reagent (120 μl, 5: 1, vol / vol). For NIH3T3, Jurkat and THP-1 cells, CTB-culture medium reagent was added directly to the cell culture medium without discarding. After incubation at 37°C and 5% CO2 for 90-100 minutes (240 min for NIH3T3, Jurkat and THP-1 cells) in a humid incubator, the samples were transferred to a black fluorescent plate and the color change of the samples was measured by a fluorescence reader at Ex560nm / Em590nm.
[0343] Table 7 – List of cell types
[0344] name type Species Growth source HeLa Cervical cancer Human Adhesion DSMZ HepG2 Liver cancer Human Adhesion CLS Neuro 2a Neuroblastoma Mouse Adhesion CLS
[0345] The performance of the modified polyamines was measured by EC50, which is the concentration of siRNA required to inhibit 50% of cell growth. At the same time, the same test was performed using an irrelevant siRNA and the EC50 value was calculated in the same way. The signal-to-noise ratio was then defined as the ratio between EC50 (control) and EC50 (PLK-1).
[0346] Table 8 - Transfection and signal-to-noise ratios for modified polyamines
[0347]
[0348] The data demonstrate very efficient transfection of siRNA into different cell types, including cells grown in suspension. The transfection reaction was very well tolerated by the cells, with minimal or no toxicity signals, indicated by a signal-to-noise ratio of 3 or higher.
[0349] Example 9 - Transfection efficiency and signal-to-noise ratio of commercial reagents
[0350] In the same experiment as described in Example 8, several commercial transfection agents were tested in parallel and the results of this experiment are listed in Table 9.
[0351] Commercial transfection agents: Interferin (Polyplus, France), Ribocellin (BioCell Challenge, Germany), TransIT-TKO (Mirus, US), siPort NeoFX (Ambion / Lifetechnologies Corp.), Dharmafect (Dharmacon / Thermo Fisher) and LipofectamineRNAiMAX (Invitrogen / Life Technologies Corp.) were processed according to the manufacturer's instructions and complexed with Plk1 and scr siRNA. Serial dilutions were performed in OptimemI (Gibco / Life Technologies) to obtain siRNA concentrations on cells ranging from 100 nM to 2 nM.
[0352] Table 9 – Transfection and signal-to-noise ratios of commercial reagents
[0353]
[0354] Although transfection was achievable in many cases, particularly with the reagents Dharmafect and RNAiMAX, the signal-to-noise ratio was significantly reduced throughout the tests.
[0355] Example 10 - Analytical Characterization
[0356] Transfection reagents: 5 mmol of branched PEI was modified with 11-bromondecanoic acid methyl ester and nonyl bromide as described in Example 1, and all other reagents were scaled accordingly. Alkylating agents were added to give a degree of substitution of about 40% and a ratio between modifiers of about 1. Modified Pei was purified from the reaction mixture by size exclusion chromatography in 10 mM NaOH, 70% ethanol.
[0357] Analysis: The estimated PEI concentration at this point is about 60 mM (based on monomer). 1 mL of the solution was mixed with 0.5 mL of 100 mM methoxyacetic acid and 25 μl of 2N NaOH. The mixture was dried under vacuum, dissolved in 700 μl CD3OD and analyzed by 1H NMR. Signals: methoxyacetic acid 4.0 ppm; bPEI backbone 2.4-2.7 ppm, terminal CH3 of the alkyl portion 0.8 ppm and terminal CH2-COOH of the carboxyalkyl 2.1 ppm.
[0358] Table 10 – Analysis of 1H NMR spectra
[0359]
[0360] Example 11: More polyamine derivatives
[0361] The following polyamines were subjected to the modification reaction described in Example 1:
[0362] Table 11: Polyamines
[0363]
[0364] The polymer was dissolved in anhydrous ethanol at a concentration of 250 mono-mM; ie, the nitrogen concentration was 250 mM.
[0365] The carboxyl compound used for polyamine modification is selected from Table 12 below and dissolved in anhydrous ethanol at a concentration of 250 mM:
[0366] Table 12: Carboxyl compounds for polyamine modification
[0367]
[0368] The hydrophobic compounds used for polyamine modification were selected from Table 13 below and were also dissolved in anhydrous ethanol at a concentration of 250 mM:
[0369] Table 13: Hydrophobic compounds for polyamine modification
[0370]
[0371]
[0372] K2CO3 was used as a 6M aqueous solution.
[0373] For modification of 100 μmol of polyamine (based on monomer), pipette the following solutions per reaction:
[0374] -400 μl polyamine solution
[0375] -X μl ω-bromocarboxylate
[0376] -Yμl of brominated hydrocarbons
[0377] - Up to 650 μl of absolute ethanol
[0378] -33 μl K2CO3
[0379] The combined amounts of X+Y are selected to provide a degree of substitution of the polyamine amino groups from 0 to 100%, and X and Y are further selected to complement each other and give various C / A ratios between 0 (hydrophobic substituents only) and carboxyl substituents only (denoted as C / A=99 in the table below).
[0380] All mixtures were sealed and incubated in an oven at 60°C for 7 days. Afterwards, 250 μl of 2N NaOH was added, the mixtures were sealed again and incubated at 60°C for another 2 days. For the initial tests, a small aliquot of the reaction mixture was taken and diluted 1:100 in 75% ethanol / water. 42 μl of each diluted sample was transferred to a 96-well plate and dried.
[0381] Example 12: Transfection of siRNA using modified polyamines.
[0382] The modified polyamines from Example 11 were complexed with siRNA targeting PLK-1 and tested for their transfection properties as described in Examples 2 to 6, except that buffer F (10 mM NaH2PO4, 225 mM sucrose, pH 7.2 (adjusted with NaOH)) was used for siRNA complexation and transfection.
[0383] The results of the transfection reactions are reported in Table 14 for the modified polyamines in which the hydrophobic portion is an aliphatic alkyl or cycloalkyl group and in Table 15 for the modified polyamines in which the hydrophobic group is an aryl or alkylaryl group.
[0384] Table 14: Transfection of siRNA using certain polyamines where the lipophilic group is an alkyl group. Lower numbers indicate successful cell transfection and values <= 50 are highlighted.
[0385]
[0386] The data in Table 14 demonstrate that many modified polyamines are capable of transfecting cells with siRNA. The hydrophobic group is selected from an aliphatic alkyl moiety or a cycloalkyl moiety, and both result in the formation of active carriers regardless of their structural differences.
[0387] The active supports are formed from polyamines having a wide range of different molecular weights and different structures (linear or branched). It is also evident from the data that the carboxyl and hydrophobic components act synergistically, and that a single modification has little, if any, contribution to support performance.
[0388] Table 15: Transfection of siRNA using certain polyamines where the hydrophobic group is aryl, alkylaryl or heteroaryl.
[0389]
[0390] The data in Table 15 demonstrate that many modified polyamines are capable of transfecting cells with siRNA. The hydrophobic groups are selected from aryl or alkylaryl moieties, and all result in the formation of active carriers regardless of their structural differences.
[0391] The active supports are formed from polyamines having a wide range of different molecular weights and different structures (linear or branched). It is also evident from the data that the carboxyl and hydrophobic components act synergistically, and that a single modification has little, if any, contribution to support performance.
[0392] Example 13: Transfection of plasmid
[0393] Cell culture: HeLa cells were cultured in 100 μl of RPMI1640 medium (PAA Lab GmbH) supplemented with 10% FCS (Sigma-Aldrich), 1x Pen / Strep (PAAlab GmbH) solution (according to the manufacturer's instructions) and seeded in 96-well plates at a density of 8000 cells / well. Cells were cultured in a humidified incubator at 37°C and 5% CO2. 24 hours after plating, cells were provided with fresh complete medium and transfected on the same day.
[0394] Complexation: Polyamine was provided in a 96-well plate, each well contained 3 mM polymer in 70% ethanol, plasmid-DNA (pCMV-Luc) was provided as a 0.011 μg / μl stock solution in buffer F (10 mM NaH2PO4, 225 mM sucrose, pH 7.2 (adjusted with NaOH)). 10 μl of polyamine was complexed with 90 μl of plasmid-DNA by mixing. 10-15 minutes after complexation, 10 μl of the mixture was used to transfect HeLa cells, resulting in 100 ng of plasmid-DNA / well.
[0395] Determine the expression of luciferase: After 24 hours of transfection, prepare cells for quantitative detection of luciferase. Therefore, the culture plate is balanced to room temperature for about 10 minutes. After discarding the culture medium, the cells are washed once with PBS. Utilize 100 μl of 1xBeetle Lysis Juice (PJK GmbH, Germany) to lyse the cells and prepare for luminescence measurement after 5 minutes. Utilize TECAN fluorescent plate reader to quantify the expression of luciferase.
[0396] Example 14: Results of plasmid transfection
[0397] The modified polyamines from Example 11 were complexed with plasmids and tested for their transfection properties as described in Example 13.
[0398] For modified polyamines in which the lipophilic portion is an aliphatic alkyl or cycloalkyl group, the results of the transfection reactions are recorded in Table 16, for modified polyamines in which the lipophilic group is an aryl or alkylaryl group, the results of the transfection reactions are recorded in Table 17, and for modified polyamines in which the carboxyl portion comprises an aryl or alkylaryl group, the results of the transfection reactions are recorded in Table 18.
[0399] Table 16: Luminescence measured when HeLa cells were transfected with plasmids using certain polyamines in which the hydrophobic group is an aliphatic alkyl group. For clarity, signals below 100 light units are omitted and signals above 5000 light units are underlined.
[0400]
[0401]
[0402]
[0403]
[0404] The data in Table 16 demonstrate that many carboxylated, hydrophobized polyamines are capable of transfecting plasmids into cells. The hydrophilic group is selected from an aliphatic alkyl moiety or a cycloalkyl moiety, and all result in the formation of active carriers regardless of their structural differences.
[0405] The active supports are formed from polyamines having a wide range of different molecular weights, different structures (linear or branched) and different chemical compositions (polyethyleneimine, polyallylamine, polyvinylamine). It is also evident from the data that the carboxyl and hydrophobic components act synergistically, and that a single modification has little, if any, contribution to support performance.
[0406] Table 17: Transfection of plasmids using certain polyamines in which the hydrophobic group is an aryl or alkylaryl group. For clarity, signals below 100 light units are omitted and signals above 5000 light units are underlined.
[0407]
[0408]
[0409]
[0410] The data in Table 17 demonstrate that many carboxylated, hydrophobized polyamines are capable of transfecting cells with plasmids. The hydrophobic group is selected from aryl or alkylaryl moieties, and all result in the formation of active carriers regardless of their structural differences.
[0411] The active supports are formed from polyamines having a wide range of different molecular weights, different structures (linear or branched) and different chemical compositions (polyethyleneimine, polyallylamine). It is also evident from the data that the carboxyl and hydrophilic components act synergistically, and that a single modification has little, if any, contribution to support performance.
[0412] Table 18: Transfection of plasmids with certain polyamines in which the carboxyl group comprises an aryl or alkylaryl group. For clarity, signals below 100 light units are omitted and signals above 5000 light units are underlined.
[0413]
[0414]
[0415] The data in Table 18 demonstrate that many carboxylated, hydrophobized polyamines are capable of transfecting cells with plasmids. The carboxyl group is selected from carboxylic acids containing an aryl or alkylaryl moiety and, regardless of their structural differences, results in the formation of an active carrier.
[0416] The active supports are formed from polymers having a wide range of different molecular weights or different structures. It is also evident from the data that the carboxyl groups and the hydrophobic component act synergistically, and that a single modification has little, if any, contribution to support performance.
[0417] Example 15: Synthesis of various carboxylated, hydrophobized oligospermines and their homologues
[0418] From commercially available 1,4-diaminobutane ( 1 ) and three steps of synthesis to obtain an important intermediate 21 .
[0419] Reaction Scheme 1: Important intermediates 21 The synthetic route
[0420]
[0421] By adding acrylonitrile to 1,4-diaminobutane ( 1 ) Compounds are easily obtained 2 After this, two boc-protecting groups were introduced into the molecule to give the compound 3 The nitrile is then reduced with hydrogen in the presence of excess butylamine to give 21 .
[0422] Reaction Scheme 2: Oligomerization
[0423] To form oligospermines, 21 was reacted with 1,4-dichlorobut-2-in under standard alkylation conditions to give dimer 41, trimer 42, and a series of longer oligomers:
[0424]
[0425] Unfortunately, the N-CH2-C≡C moiety is unstable and easily cleaved. Therefore, the compound 41, 42 The triple bonds of oligomers of 1, 2 or 3 Å are reduced, followed by removal of the Boc-group.
[0426] Use 1,5-diaminopentane or 1,6-diaminohexane as starting material 1 Similar reactions are performed to obtain a series of oligospermine homologues or polyalkyleneimines, wherein the variable x represents the spacing between the nitrogen groups varying between 2 and 3, 2 and 4, or 2 and 5.
[0427] In addition to forming oligospermine homologues, the size of the hydrophobic substituent was systematically varied between butyl (as described in this example), ethyl, hexyl and decyl, resulting in a matrix of different polyalkyleneimines varying in their alkylene groups, their hydrophobic substituents and their degree of oligomerization.
[0428] Oligospermine and its homologues (all polyalkyleneimines of this example) were desalted using Sephadex G25 and the individual oligomers were purified using ion exchange chromatography on fast flow CM-Sepharose Fast Flow and fast flow SP-Sepharose Fast Flow. Oligospermine was eluted from the ion exchange column according to its degree of polymerization and indicated using Roman numerals I to XII, whereby higher numbers represent longer oligomers. The degree of polymerization was determined using mass spectrometry and ranged from trimers to about 20-mers.
[0429] Fractions containing the isolated oligomers were extracted from the buffer using dichloromethane under basic conditions, dried under vacuum and dissolved in absolute ethanol at 250 mM nitrogen.
[0430] In a subsequent step, using the general protocol of Example 11, 50 μmol samples of each oligomer were derivatized with 0, 10, 15, 20 or 25 μmol of ω-bromocarboxylic acids C3, C6, C8, C11 and C16.
[0431] Example 16: Transfection of cells using carboxy-hydrocarbon-oligospermine
[0432] Transfection experiments with various carboxylated and hydrophobized oligospermines and their respective homologues were performed using the siRNA targeting PLK-1, HeLa cells, and cell culture conditions and assays described in Examples 2 to 7.
[0433] Table 19 below is a table of the results obtained using carboxy-hydrocarbon-oligospermine as a transfection agent for siRNA.
[0434] Table 19: Inhibition of cell viability of HeLa cells when transfected with cytotoxic siRNA using carboxylated, hydrophobized oligospermine. The number x represents the oscillating length of the alkylene unit according to formula (1), and the Roman numerals used for the oligomers represent the degree of polymerization of the oligomers. The numbers in the table indicate the remaining cell viability, with low numbers indicating efficient transfection.
[0435]
[0436]
[0437] The data in Table 19 demonstrate that many carboxylated, hydrophobized oligospermines are capable of transfecting cells. Active carriers are formed from oligospermines having a wide range of different molecular weights and different molecular structures due to variations in spacing between nitrogen atoms. It is also apparent from the data that the carboxyl and hydrophobic components act synergistically, as alkylated oligospermines show little, if any, contribution in cell transfection, while the introduction of the carboxyl moiety results in an active carrier structure.
[0438] Example 17: Neutral and Anionic Particles from Modified Polyamines and Nucleic Acids
[0439] Prepare a buffer containing 280 mM sucrose, 10 mM sodium dihydrogen phosphate, and 3 mM sodium hydroxide (pH 6.5) or 7 mM sodium hydroxide (pH 7.2). Prepare the siRNA stock solution from Example 5 in the buffer to give a concentration 10 times that listed in Table 20.
[0440] The modified polyamine of Example 8 was provided in the form of a solution of 56 mM (in mono-mM) of the modified polyamine in 70% ethanol, 10 mM sodium hydroxide; 50 μl of the modified polyamine solution was quickly mixed with 4.1 ml of any buffer. A colloid was formed, and the particle size and zeta potential of the dispersed phase were measured using a MALVERN Zetasizer 3000HSA.
[0441] 900 μl of each siRNA solution was quickly mixed with a dispersion of the modified polyamine in buffer to give the N / P ratios listed in Table 20, and the size and zeta potential were again recorded.
[0442] Table 20: Size and zeta potential of complexes between modified polyamines with various N / P ratios and siRNA.
[0443]
[0444] General observations: The modified polyamines did form particles with a size of about 500 nm and nearly neutral zeta potential. The addition of small amounts of siRNA resulting in an N / P ratio of 12 or higher did not substantially change the size or surface charge of the particles. However, the addition of larger amounts of siRNA resulted in the formation of anionic particles of approximately the same size. Moderate amounts of siRNA resulted in intermediate zeta potentials and the formation of aggregates. The system behavior can be understood as the interaction of two polyelectrolytes with opposite charges, where aggregation occurs under charge neutralization conditions as described by Endert et al. (2004) "Nanocapsules from liposomal templates", pp. 238-248 in Carrier Based Drug Delivery, Oxford University Press.
[0445] Specific observation: At pH 6.5, charge reversal toward a fully anionic state requires an N / P of 4, whereas at pH 7.2 the same process is complete at an N / P of 6. This observation is consistent with stronger ionization of the PEI backbone amines at lower pH values.
[0446] Example 18: Lyophilized transfection agent
[0447] The modified polyamine of Example 8 was provided as a solution with a nitrogen concentration of 56 mM in 70% ethanol, 10 mM sodium hydroxide. Various amounts of the clear solution of the transfection agent were rapidly injected into a homogenous phase containing 280 mM sucrose and 20 mM sodium phosphate adjusted to pH 6.5 with NaOH to give a final concentration of 0.15 mM or 0.03 mM transfection agent. For samples containing 0.15 mM or 0.03 mM nitrogen, the average particle size and polydispersity were 389 nm (PI of 0.09) and 332 nm (PI of 0.11), respectively.
[0448] Aliquots of 100 μl were placed in 96-well plates. The material was frozen at -18°C for 4 hours and transferred to a freeze dryer. Lyophilization was carried out at a constant pressure of 0.12 mbar for 20 hours. After removal from the freeze drying chamber, the plates were quickly sealed using a heat sealer.
[0449] On the next day, the seal was broken and the sample was rehydrated with water. The lyophilized product dissolved quickly and evenly. Particle size and polydispersity were determined as described above.
[0450] Within 15 minutes after the start of rehydration, when 15 nmol of transfection reagent was placed in each well, the resulting colloidal transfection reagent had an average particle size of 423 nm (PI 0.13). When 3 nmol of transfection reagent was placed in each well, the resulting colloidal transfection reagent had an average particle size of 356 nm (PI 0.12).
[0451] The contents of European patent application No. 12 006 963.8 (filed on October 8, 2012), from which priority is claimed, including all claims and the entire specification, are incorporated herein by reference.
Claims
1. A polyamine derivative for transfecting nucleic acid into a cell, the polyamine derivative comprising: a polyamine moiety comprising a plurality of amino groups; a plurality of carboxylated substituents comprising a carboxyl group bound to an amino group of the polyamine moiety via a hydrophobic linker, wherein each of the carboxylated substituents comprises 6 to 40 carbon atoms, and each of the hydrophobic linkers may comprise 1 to 3 heteroatoms selected from O, N, and S; and a plurality of hydrophobic substituents bonded to the amino groups of the polyamine moieties, wherein each of the hydrophobic substituents comprises 2 to 40 carbon atoms and may comprise 1 to 3 heteroatoms selected from O, N and S when the hydrophobic substituents have at least 6 carbon atoms, The polyamine derivative is a linear polyalkylene imine derivative comprising a unit represented by the following formula (10): -[CH2-NR 10 -(CH2) x ]-(10) in x is an integer from 1 to 10, wherein in different (CH2) x The value of x can be the same or different between groups. R 10 For hydrogen, A carboxylated substituent comprising a carboxyl group connected to a binding R via a hydrophobic linker. 10 The amino nitrogen of Hydrophobic substituents, When different R 10 When , it is independently selected from the above groups; or The polyamine derivative is a branched polyalkylene imine derivative, and the branched polyalkylene imine derivative comprises a unit represented by each of formula (11), formula (12) and formula (13): -[CH2-NR 10 -(CH2) x ]-(11) -[CH2-NR 11 -(CH2) x ]-(12) and -(CH2) y -NR 10 2(13) in R 10 and x are as defined above; R 11comprising one or more units selected from formula (11), formula (12) and formula (13); y is an integer from 1 to 10, wherein in different (CH2) y The value of y may be the same or different between groups; and The number of nitrogen atoms per molecule of the linear polyalkyleneimine or the branched polyalkyleneimine is 12 to 100,000.
2. The polyamine derivative according to claim 1, wherein each of the carboxylated substituents contains 6 to 20 carbon atoms.
3. The polyamine derivative according to claim 1, wherein each of the hydrophobic substituents contains 6 to 40 carbon atoms.
4. The polyamine derivative according to claim 1, wherein each of the carboxylated substituents contains 6 to 20 carbon atoms, and each of the hydrophobic substituents contains 6 to 40 carbon atoms. 5 . The polyamine derivative according to claim 1 , wherein the hydrophobic substituent comprises an aryl group and has 6 to 20 carbon atoms. The polyamine derivative according to claim 5 , wherein the aryl group is an aromatic hydrocarbon group or an aromatic heterohydrocarbon group.
7. The polyamine derivative according to claim 1, wherein the carboxylated substituent is a carboxyalkyl substituent and the hydrophobic substituent comprises an aryl group.
8. The polyamine derivative according to claim 1, wherein the polyamine moiety comprises 20 to 5000 nitrogen atoms. 9 . The polyamine derivative according to claim 1 , wherein a molar ratio of the carboxylated substituent to the hydrophobic substituent in the polyamine derivative is in the range of 10:1 to 0.1:
1. 10 . The polyamine derivative according to claim 9 , wherein the molar ratio of the carboxylated substituent to the hydrophobic substituent in the polyamine derivative is in the range of 3:1 to 0.33:
1. 11 . The polyamine derivative according to claim 7 , wherein a molar ratio of the carboxylated substituent to the hydrophobic substituent in the polyamine derivative is in the range of 10:1 to 0.1:
1. 12 . The polyamine derivative according to claim 7 , wherein the molar ratio of the carboxylated substituent to the hydrophobic substituent in the polyamine derivative is in the range of 3:1 to 0.33:
1.
13. The polyamine derivative according to claim 1, wherein the polyamine derivative is a carboxyalkyl-alkyl-polyamine, wherein the carboxylated substituent of the polyamine derivative is a carboxyalkyl moiety, and the hydrophobic substituent of the polyamine derivative is an alkyl moiety; and wherein all the carboxyalkyl moieties of the carboxyalkyl-alkyl-polyamine are the same and all the alkyl moieties are the same, and the total number of carbon atoms in the carboxyalkyl moieties and the alkyl moieties is from 10 to 30. 14 . The polyamine derivative according to claim 13 , wherein the total number of carbon atoms in the carboxyalkyl portion and the alkyl portion is 15 to 25.
15. The polyamine derivative of claim 1, wherein the polyamine derivative has a branched polyethyleneimine portion having a number average molecular weight of 0.5 to 200 kDa, the carboxylated substituent has 11 to 16 carbon atoms and is a normal alkyl carboxylic acid group, and the hydrophobic substituent has 6 to 12 carbon atoms and is an aromatic group.
16. The polyamine derivative of claim 15, wherein the hydrophobic substituent comprises a benzyl, propylbenzyl, naphthyl or indolyl moiety.
17. A polyamine derivative for transfecting a nucleic acid into a cell, the polyamine derivative comprising: a polyamine moiety comprising a plurality of amino groups; a plurality of carboxylated substituents comprising a carboxyl group and a hydrophobic linker, wherein the carboxylated substituents are bonded to the amino group of the polyamine portion via the hydrophobic linker; and a plurality of hydrophobic substituents, the hydrophobic substituents being bonded to the amino groups of the polyamine moieties, The polyamine derivative is a linear carboxyalkyl-alkyl-polyalkyleneimine containing a unit represented by the following formula (6): -[CH2-NR 6 -(CH2) x ]-(6) in x is an integer from 1 to 10, wherein in different (CH2) x The value of x can be the same or different between groups. R 6 For hydrogen, C r H 2r+1 or C s-1 H 2s-2 COOH, when different R 6 , which are independently selected from the above groups, r is an integer from 2 to 40, s is an integer from 4 to 40; or The carboxyalkyl-alkyl-polyamine is a branched carboxyalkyl-alkyl-polyalkyleneimine, and the branched carboxyalkyl-alkyl-polyalkyleneimine comprises a unit represented by each of formula (7), formula (8) and formula (9): -[CH2-NR 6 -(CH2) x ]-(7) -[CH2-NR 7 -(CH2) x ]-(8) and -(CH2) y -NR 6 2(9) in R 6 , x, r and s are as defined above; R 7 comprising one or more units selected from formula (7), formula (8) and formula (9); y is an integer from 1 to 10, wherein in different (CH2) y The value of y may be the same or different between groups; and The number of nitrogen atoms per molecule of the linear carboxyalkyl-alkyl-polyalkyleneimine or the branched carboxyalkyl-alkyl-polyalkyleneimine is 12 to 100,000.
18. The polyamine derivative according to claim 17, wherein at least 10 mol% of the amino groups of the polyamine are substituted by the carboxyalkyl group and the alkyl group.
19. The polyamine derivative according to claim 18, wherein 25 to 80 mol% of the amino groups of the polyamine are substituted with the carboxyalkyl group and the alkyl group.
20. The polyamine derivative of claim 17, wherein each of the carboxylated substituents contains 6 to 20 carbon atoms.
21. The polyamine derivative of claim 17, wherein each of the hydrophobic substituents comprises 6 to 40 carbon atoms.
22. The polyamine derivative of claim 17, wherein each of the carboxylated substituents contains 6 to 20 carbon atoms, and each of the hydrophobic substituents contains 6 to 40 carbon atoms.
23. The polyamine derivative according to claim 17, wherein the number of nitrogen atoms per molecule of the linear carboxyalkyl-alkyl-polyalkyleneimine or the branched carboxyalkyl-alkyl-polyalkyleneimine is 20 to 5000.
24. The polyamine derivative according to claim 17, wherein the molar ratio of the carboxylated substituent to the hydrophobic substituent in the polyamine derivative is in the range of 10:1 to 0.1:
1.
25. The polyamine derivative according to claim 24, wherein the molar ratio of the carboxylated substituent to the hydrophobic substituent in the polyamine derivative is in the range of 3:1 to 0.33:
1.
26. Use of the polyamine derivative according to any one of claims 1 to 16 in the production of a transfection reagent for transfecting nucleic acids into cells.
27. The use according to claim 26, wherein the nucleic acid is RNA.
28. The use according to claim 27, wherein the RNA is mRNA.
29. Use of a polyamine derivative according to any one of claims 17 to 25 in the production of a transfection reagent for transfecting a nucleic acid into a cell.
30. The use according to claim 29, wherein the nucleic acid is RNA.
31. The use according to claim 30, wherein the RNA is mRNA.
32. A complex of a nucleic acid or a protein with a polyamine derivative as defined in any one of claims 1 to 16.
33. A complex of a nucleic acid or a protein with a polyamine derivative as defined in any one of claims 17 to 25.
34. A kit comprising: (i) a polyamine derivative as defined in any one of claims 1 to 16, (ii) a buffer solution having a pH between 4 and 8, and (iii) Optionally, an instruction manual.
35. The kit according to claim 34, wherein the polyamine derivative is provided in the form of a solution, and wherein the solvent of the solution is a lower alcohol selected from the group consisting of ethanol, propanol, 1,2-dihydroxypropane or isopropanol, or a mixture comprising water and 33 to 100% of such a lower alcohol.
36. The kit of claim 34, wherein the polyamine derivative is provided in dry form.
37. The kit according to claim 36, wherein the polyamine derivative is provided in a lyophilized form.
38. A kit comprising: (i) a polyamine derivative as defined in any one of claims 17 to 25, (ii) a buffer solution having a pH between 4 and 8, and (iii) Optionally, an instruction manual.
39. The kit according to claim 38, wherein the polyamine derivative is provided in the form of a solution, and wherein the solvent of the solution is a lower alcohol selected from the group consisting of ethanol, propanol, 1,2-dihydroxypropane or isopropanol, or a mixture comprising water and 33 to 100% of such a lower alcohol.
40. The kit of claim 38, wherein the polyamine derivative is provided in dry form.
41. The kit of claim 40, wherein the polyamine derivative is provided in lyophilized form.
42. A non-therapeutic method using nucleic acid transfection of cells, comprising: The nucleic acid is mixed with a polyamine derivative as defined in any one of claims 1 to 16, and the cell is treated with the mixture obtained in the previous step.
43. The method of claim 42, comprising mixing the nucleic acid with the polyamine derivative in an aqueous buffer.
44. A non-therapeutic method using nucleic acid transfection of cells, comprising: The nucleic acid is mixed with a polyamine derivative as defined in any one of claims 17 to 25, and the cells are treated with the mixture obtained in the previous step.
45. The method of claim 44, comprising mixing the nucleic acid with the polyamine derivative in an aqueous buffer.
